High Times Ahead: Products Liability in Medical Marijuana by Perlmutter, Steven B.
Masthead Logo Health Matrix: The Journal of Law-Medicine
Volume 29 | Issue 1
2019
High Times Ahead: Products Liability in Medical
Marijuana
Steven B. Perlmutter
Follow this and additional works at: https://scholarlycommons.law.case.edu/healthmatrix
Part of the Health Law and Policy Commons
This Article is brought to you for free and open access by the Student Journals at Case Western Reserve University School of Law Scholarly Commons.
It has been accepted for inclusion in Health Matrix: The Journal of Law-Medicine by an authorized administrator of Case Western Reserve University
School of Law Scholarly Commons.
Recommended Citation
Steven B. Perlmutter, High Times Ahead: Products Liability in Medical Marijuana, 29 Health Matrix 225 (2019)
Available at: https://scholarlycommons.law.case.edu/healthmatrix/vol29/iss1/7
Health Matrix 29·Issue 1·2019 
225 
High Times Ahead: 
Products Liability in Medical 
Marijuana 
Steven B. Perlmutter† 
Contents 
Introduction .................................................................................. 226 
I. The Basics ................................................................................... 227 
A.  Marijuana .................................................................................... 227 
B.  Supply Chain ................................................................................ 231 
II. Federal and State Medical Marijuana Law ............................ 232 
A.   Federal Marijuana Law ................................................................ 232 
B.   State Marijuana Law ................................................................... 233 
III. Medical Marijuana as a “Pharma-pseudical” .......................... 235 
A.  Alcohol ........................................................................................ 235 
B.  Tobacco ....................................................................................... 237 
C.  Nutritional Supplements ................................................................ 237 
D.  Pharmaceuticals ........................................................................... 238 
IV. Health Effects of Cannabis & Cannabinoids .......................... 242 
A.  Beneficial Effects of Cannabinoids ................................................. 242 
B.  Adverse Effects of Cannabinoids .................................................... 246 
V. Manufacturing Defects ............................................................ 255 
A.  General Considerations ................................................................. 255 
B.  Medical Marijuana Manufacturing Defect Claims ............................ 257 
1. Pesticides ........................................................................................ 257 
2. Heavy Metals and Fungus ............................................................... 261 
3. Inaccurate Medical Marijuana Testing ............................................ 261 
VI. Defective Design ...................................................................... 264 
A.  Theory ......................................................................................... 264 
B.  Defective Design in Medical Marijuana ........................................... 266 
VII. Failure to Warn ..................................................................... 269 
A.  General Considerations ................................................................. 269 
B.  Warnings About Pharmaceuticals ................................................... 270 
C.  Failure to Warn and Adequately Label Marijuana Products .............. 273 
1. Kirk v. Nutritional Elements .......................................................... 274 
2. One Candy Bar: Sixteen Servings ................................................... 278 
D.  Suggestions for Reasonable Packaging and Verbal Warnings ............. 278 
 
†  Steven B. Perlmutter, M.D. (Washington University School of Medicine), 
J.D. (Sandra Day O’Connor College of Law) is an attorney practicing 
exclusively in the area of health law in Scottsdale, Arizona. Previously, 
he practiced as a board-certified ophthalmologist for 25 years in the 
Phoenix metropolitan area.  
Health Matrix·Volume 29·Issue 1·2019 
High Times Ahead:  Products Liability in Medical Marijuana 
226 
E.  Labeling and Packaging ................................................................. 281 
VIII. Youth Marketing of Marijuana ............................................ 285 
IX. Conclusion ................................................................................ 290 
 
Introduction 
Medical marijuana is big business. In 2016, Arizonans purchased 
twenty-nine tons of cannabis products, a fifty-three percent increase 
from 2015.1 Nearly 115,000 new patients registered for medical cannabis 
in Arizona, a thirty percent increase over 2015.2 The state received 
$29.5 million in tax revenue from medical marijuana in 2016.3 Total 
marijuana sales in North America exceeded $6.7 billion in 20164 and the 
estimated impact on the U.S. economy in 2020 could reach $44 billion.5 
From January 1, 2017 through October 13, 2017, $1.9 billion of new 
capital was raised and invested in the cannabis industry.6 
Big business typically sparks big litigation, but medical marijuana 
and products liability have been virtual strangers. They will not be for 
long. While only two cannabis products liability cases have been filed 
in the United States to date (both in Colorado),7 it is easy to envision 
dozens, if not hundreds, of cases being filed in the next decade. This 
paper considers the basis for potential claims and the actions the 
industry can take now to increase patient safety and mitigate liability. 
 
1. Eli McVey, Arizona Medical Marijuana Patient Count in 2016, 
MARIJUANA BUS. DAILY (Feb. 6, 2017), mjbizdaily.com%2Fchart-arizona-
growing-intomedical-marijuana-juggernaut%2F. 
2. Eli McVey, Arizona Growing into Medical Marijuana Juggernaut, 
MARIJUANA BUS. DAILY (Feb. 06, 2017), http://mjbizdaily.com/chart-
arizona-growing-into-medical-marijuana-juggernaut. 
3. Ray Stern, Arizona Medical Marijuana Sales Hit Record High: We Bought 
29 Tons in ‘16, State Got $29.5 Million in Taxes, PHOENIX NEW TIMES 
(Jan. 24, 2017), https://www.phoenixnewtimes.com/news/arizona-
medical-marijuana-sales-hit-record-high-we-bought-29-tons-in-16-state-
got 295-million-in-taxes-9018620. 
4. Debra Borchardt, Marijuana Sales Totaled $6.7 Billion in 2016, FORBES 
(Jan. 3, 2017, 9:00 AM), https://www.forbes.com/sites/debraborchardt 
/2017/01/03/marijuana00000-sales-totaled-6-7-billion-in-2016/ 
#2ca7610a75e3.  
5. David Schepp, Legal Marijuana: A $44 Billion Business by 2020?, CBS 
MONEYWATCH (Mar. 18, 2016, 5:30 AM), https:// www.cbsnews.com 
/news/legal-marijuana-a-44-billion-business-by-2020/. 
6. Cannabis Deal Tracker: Investment and M&A Activity in the Cannabis 
Industry, VIRIDIAN CAPITAL ADVISORS, http://mailchi.mp/viridianca 
/deal-tracker-2930261 (last visited Sep. 29, 2018). 
7. See, e.g. Compl. at 2, Flores v. Livwell Inc. (D. Colo. 2015) (No. 
2015CV33528); Am. compl. at 7, Kirk v. Nutritional Elements, Inc. (D. 
Colo.) (No. 16CV31310). 
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Part I discusses basic information about medical marijuana and its 
supply chain of production. Part II explores current federal and state 
law. Part III suggests a paradigm for medical marijuana liability. 
Potential regulation for medical marijuana is explored by comparison 
to similar products that are subject to varying regulations. Part IV 
describes our current knowledge of the therapeutic and adverse effects 
of medical marijuana. It also highlights that more research is needed to 
fully understand and educate users about the risks and benefits of 
medical marijuana. Part V considers manufacturing defects as a theory 
of product liability. Part VI discusses defective design related to the 
unregulated nature of medical cannabis, while Part VII explores the 
current system’s failure to warn. Finally, Part VIII examines the special 
problem of youth marketing. 
I. The Basics 
A. Marijuana 
Marijuana is a plant, more specifically a greenish-gray mixture of 
dried flowers from Cannabis sativa.8 It is referred to by a wide variety 
of names, including cannabis, weed, herb, pot, grass, bud, ganja, 420, 
and Mary Jane.9 Individuals and corporations on the cutting edge of 
the marijuana industry are called “ganjapreneurs.”10 
Marijuana is used for both recreational and medical purposes.11 This 
article focuses on medical marijuana, particularly in edible form. 
According to the National Institute on Drug Abuse, a division of 
National Institutes of Health (NIH), “medical marijuana refers to using 
the whole, unprocessed marijuana plant or its basic extracts to treat 
symptoms of illness and other conditions.”12 Web MD defines medical 
marijuana as “the use of this drug to help treat symptoms like pain, 
muscle stiffness (spasticity), nausea, and lack of appetite. It may be 
used by people who have conditions like cancer, AIDS, or multiple 
 
8. Marijuana as Medicine, NIH NAT’L INST. ON DRUG ABUSE, 
https://www.drugabuse.gov/publications/drugfacts/marijuana-medicine 
(last updated June 2018). 
9. What is Marijuana?, NIH - NAT’L INST. ON DRUG ABUSE, https:// 
www.drugabuse.gov/publications/research-reports/marijuana/what-
marijuana (last updated June 2018). 
10. Madhura Yale, Cash in on Marijuana Boom: Become a Ganjapreneur, 
JUNGLEWORKS, https://jungleworks.com/cash- marijuana-boom-become-
ganjapreneur (last visited Dec. 19, 2018). 
11. NAT’L ACAD. SCIENCES, ENG’G, & MED., THE HEALTH EFFECTS OF 
CANNABIS AND CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND 
RECOMMENDATIONS FOR RESEARCH, xvii, 1 (Nat’l Acad. Press eds., 2017), 
available at https://www.nap.edu/catalog/24625/the-health-effects-of-
cannabis-and-cannabinoids-the-current-state. 
12. Marijuana as Medicine, supra note 8. 
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sclerosis.”13 The working definition of medical cannabis for the purposes 
of this article is: the use of one or more components of the Cannabis 
sativa plant, as recommended by a licensed healthcare provider, for the 
treatment of a disease or its symptoms. 
Cannabis sativa is a complex substance, containing 545 
constituents.14 The most significant medicinal components are the 
psychoactive delta-9-trans-tetrahydrocannabinol (THC) and the non-
psychoactive cannabidiol (CBD).15 Both compounds exert effects on the 
ubiquitous endocannabinoid system.16 
The endocannabinoid system is a highly complex, endogenous 
system in the human body.17 For the purposes of this article, the two 
most important cannabinoid receptors are CB1 and CB2. The 
distribution of these receptors in various tissues accounts for the 
psychotropic and peripheral effects of THC.18 CB1 receptors are most 
abundant in the basal ganglia, cerebellum, hippocampus, and cerebral 
cortex.19 CB2 receptors are most commonly found in immune cells and 
tissues.20 By activating CB1 receptors, THC affects high-order 
behavioral activities, such as executive functioning, decision making, 
sensory responsiveness, motor function, learning, memory, and 
emotional reactions.21 Short term effects of THC on the central nervous 
system (CNS) are dose-dependent and include:22 
 
 
 
 
13. Medical Marijuana FAQ, WEBMD, http://www.webmd.com/mental-
health/tc/medical-marijuana-topic-overview#1 (last visited Oct. 11, 
2017). 
14. MAHMOUD ELSOHLY & WASEEM GUL, CONSTITUENTS OF CANNABIS SATIVA 
IN HANDBOOK OF CANNABIS, 3 (Roger G. Pertwee ed., 2014). 
15. Carola Rong et al., Cannabidiol in Medical Marijuana: Research Vistas 
and Potential Opportunities, 121 PHARMACOLOGICAL RESEARCH 213, 214 
(2017). 
16. Id. 
17. Id. 
18. See Vincenzo Di Marzo et al., The Endocannabinoid System and its 
Therapeutic Exploitation, 3 NAT’L REV. DRUG DISCOVERY 771, 772 (2004). 
19. See Debra A. Kendall et al., Cannabinoid Receptors in the Central 
Nervous System: Their Signaling and Roles in Disease, 10 FRONTIERS IN 
CELLULAR NEUROSCIENCE 1, 1(2017). 
20. Id. at 3. 
21. Bradley E. Alger, Getting High on the Endocannabinoid System, 
CEREBRUM at 4 (Nov. 1. 2013), available at https://www.ncbi.nlm.nih.gov 
/pmc/articles/PMC3997295/. 
22. Marijuana as Medicine, supra note 8. 
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 altered senses and perception 
 distorted sense of time 
 mood fluctuations 
 impaired body movement 
 disorganized thinking and problem-solving 
 diminished memory 
 hallucinations 
 delusions 
 psychosis 
The effects of CBD are less well understood. CBD interacts with 
multiple receptors in the endocannabinoid system, antagonizing CB1 
receptors but potentiating CB2 receptors.23 In contrast to THC, CBD 
has salutary effects on mood, anxiety, and sleep disturbances.24 
Cannabis can be smoked, vaporized, brewed, and ingested in foods 
and drinks.25 Administration of cannabis produces a blood level of all 
545 constituent compounds;26 however, therapeutic effects and adverse 
reactions differ based on the method of administration.27 Ingested 
components, known as edibles, have variable pharmacodynamics. Their 
effects and side effects are uncertain.28 Consequently, the 
unpredictability of their effects and the resulting enhanced potential for 
harm suggests that edibles are likely to precipitate the bulk of medical 
marijuana products liability and litigation. Thus, edibles will be the 
focus of this article. 
Marijuana edibles are food items infused with cannabis or its 
concentrates. They contain cannabinoids and are popular alternatives 
 
23. Rong et al., supra note 15, at 213-214. 
24. Rong et al., supra note 15, at 215. 
25. NAT’L ACAD. SCIENCES, ENG’G, & MED., supra note 11, at 50. 
26. Ron R. Flegel, SAMHSA’S Role: Integrating the Science & Technical 
Information into Regulated Testing, AM. SOC. ADDICTION MED. (Oct. 07, 
2016), available at https://www.asam.org/docs/default-source/education-
docs/state-of-the-art-2016/session-6- combined.pdf. 
27. NAT’L ACAD. SCIENCES, ENG’G, & MED., supra note 11, at 51. 
28. Noelle Crombie, How Potent Are Marijuana Edibles? Lab Tests Yield 
Surprising Results, MARIJUANA NEWS (Mar. 06, 2015), 
https://www.oregonlive.com/marijuana/index.ssf/2015/03/how_potent
_are_marijuana_edibl.html. 
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to smoking or vaporizing cannabis.29 Edibles became popular after Alice 
B. Toklas created and published a recipe for Hashish Fudge in her 1954 
cookbook.30 The recipe was published in the British edition but omitted 
from the U.S. edition until the second publishing in the early 1960’s.31 
The craze was popularized by the movie, I Love You, Alice B. Toklas, 
in which the conservative Peter Sellers was introduced to hash brownies 
by a hippie.32 Edibles come in many forms, often reminiscent of products 
found in a supermarket, candy store, or bakery. Here is a partial list: 
 
 Beverages – soda, tea, coffee, beer, lemonade, smoothies 
 
 Breakfast – rice crispy cereal bars, fruit and nut snacks, 
breakfast bars, croissants, madeleines, and oat squares 
 
 Brownies 
 
 Candy – gummy worms, gummy bears, caramels, sour drops, 
dried pineapple, fruit chews, mints, jellies, caramel popcorn, 
pastilles, coconut almond candy bars, apple rings, lollipops, 
lozenges, taffy, gourmet fruit slices, lemon drops, and peanut 
butter bars 
 
 Chocolates – white, milk and dark bars (plain, raisins, nuts, 
peanut butter, or caramel) and peppermint patties 
 
 Condiments – honey, BBQ sauce, blue cheese dressing, ranch 
dressing, jelly, maple syrup, and peanut butter 
 
 Cookies – snickerdoodle, ginger snap, chocolate, oatmeal, 
butterscotch, sugar, mint, coconut, peppermint, molasses, 
lemon, peanut butter, red velvet, and gluten-free 
 
 Cooking – butter, olive oil, vegetable oil,  coconut  oil,  honey, 
vinaigrette, marinades 
 
 
29. See Daniel Barrus et al., Tasty THC: Promises and Challenges of 
Cannabis Edibles, RTI INT’L (Nov. 2016), https://www.rti.org/rti-press-
publication/tasty-thc. 
30. Dave Chachere, Alice in Wonderland: The Toklas Brownie, DOPE 
MAGAZINE (Nov. 28, 2016), https://www.dopemagazine.com/alice-
wonderland-toklas-brownie/. 
31. Layla Eplett, Go Ask Alice: The History of Toklas’ Legendary Hashish 
Fudge, SCI. AM. (Apr. 20, 2015), https://blogs.scientificamerican.com 
/food-matters/go-ask-alice-the-history-of-toklas-8217-legendary-hashish-
fudge/. 
32. Id. 
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 Snacks – rice crispy treats, bars, crackers, fish crackers, 
cupcakes, pies, baklava, macaroons, peanut butter cups, and 
mixed nut clusters.33 
B. Supply Chain 
According to the online Business Dictionary, a supply chain consists 
of a network of entities, directly or indirectly interlinked and 
interdependent, which serve the same consumer or customer.34 The 
supply chain includes raw material vendors, manufacturers, 
warehouses, distribution centers, and retailers. The three basic 
functions of a supply chain are the: (1) supply of raw materials to a 
manufacturer; (2) actual manufacturing; and (3) delivery of the finished 
product via a network of distributors and retailers to the end user.35 
Regarding medical marijuana, the supply chain can be 
diagrammatically represented as follows: 
 
Figure 1. Supply Chain Schematic 
 
Growers plant and harvest the cannabis crop. Buds, or flowers, are 
separated from the plant and processed.36 Manufacturers produce 
cannabis-infused edibles, oils, waxes, and tinctures.37 Extractions and 
final products undergo laboratory testing for purity and THC 
 
33. LEAFLY, https://www.leafly.com/products/edibles (last visited Sept. 30, 
2018). 
34. BUSINESS DICTIONARY, http://www.businessdictionary.com/ (last visited 
Sept. 27, 2018). 
35. See Cannabis Supply Chain Traceability, GITHUB (Mar. 23, 2016), 
https://github.com/CannabisReports/Cannabis-Supply-Chain-
Traceability/blob/master/cannabis-supply-chain-traceability.md; Supply 
Chain Definitions, CANADIAN SUPPLY CHAIN SECTOR COUNCIL, 
http://www.supplychaincanada.org/en/supply-chain (last visited Sept. 
23, 2018). 
36. See Arizona Cannabis Society Grower Job Description, OAKSTERDAM 
UNIVERSITY, https://oaksterdamuniversity.com/wp-content/uploads/ 
2017/10/Arizona-Cannabis-Society-Grower-Job-Description.pdf (last 
visited Sept. 30, 2018); See Max Anderson, Best Tips For Harvesting 
Cannabis, PROD. GROWER (March 11, 2018), https:// 
productiongrower.com/blogs/how-to-grow-weed/harvesting; See Your 
Guide to Drying and Curing Cannabis Buds, LEAFLY (Aug. 8, 2016), 
https://productiongrower.com/blogs/how-to-grow-weed/harvesting. 
37. Market Opportunity, BUDLIFE, https://www.budlife.net/medical-
marijuana-1/ (last visited Sept. 27, 2018). 
Cultivation → Extraction → Distribution → Retail → Patient 
                    ↕                 ↑ 
           Testing                    Physician 
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concentration.38 Physicians evaluate patients for medical marijuana 
program qualifying characteristics.39 Qualifying patients receive 
certifications and are directed to retail dispensaries that sell the finished 
products.40 
II. Federal and State Medical Marijuana Law  
A.  Federal Marijuana Law 
Marijuana is currently illegal under federal law.41 The U.S. Drug 
Enforcement Agency (DEA) classifies cannabis as a Schedule I drug.42 
“Schedule I drugs, substances, or chemicals are defined as drugs with 
no currently accepted medical use and a high potential for abuse.”43 
Other Schedule I drugs include heroin, lysergic acid diethylamide 
(LSD), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone 
(Quaalude), and peyote.44 Further, the DEA claims there is “a lack of 
accepted safety for use of the drug or other substance under medical 
supervision.”45 
On July 19, 2016, the DEA denied a petition to initiate rulemaking 
proceedings to reschedule marijuana to a classification where it could 
be used medicinally.46 Their conclusion was based on their consistent 
findings that marijuana: (1) “has a high potential for abuse;” (2) “has 
no currently accepted medical use in treatment in the United States;” 
and (3) “lacks accepted safety for use under medical supervision.”47 
 
38. See What You Need to Know About Cannabis Testing, Lab Setup and 
Training, GENIE SCI., https://www.geniescientific.com/what-you-need-to-
know-about-cannabis-testing-lab-setup-and-training (last visited Sept. 27, 
2018). 
39. Qualifying Conditions for a Medical Marijuana Card by State, LEAFLY 
(Oct. 30, 2017), https://www.leafly.com/news/health/qualifying-
conditions -for-medical-marijuana-by-state. 
40. Jeremiah Wilhelm, Understanding Medical vs. Adult-Use Cannabis 
Dispensaries, LEAFLY (Jan. 30, 2017, 1:58 PM), https://www.leafly 
.com/news/cannabis-101/what-is-a-marijuana-dispensary/print/. 
41. 21 U.S.C. § 812(b)(1) (2012). 
42. Drug Scheduling, U.S. DRUG ENF’T ADMIN., https://www.dea.gov/ 
druginfo/ds.shtml (last visited Oct. 11, 2017). 
43. Id. 
44. Id. 
45. U.S. DRUG ENF’T ADMIN., DRUGS OF ABUSE: A DEA RESOURCE GUIDE 
(2017), available at https://www.dea.gov/documents/2017/06/15/drugs-
abuse. 
46. Denial of Petition to Initiate Proceedings to Reschedule Marijuana, 18 
Fed. Reg. 53767 (Aug. 12, 2016). 
47. Id. 
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Although cannabis is illegal under federal law, enforcement of those 
laws was guided by the 2013 Cole Memorandum entitled, “Guidance 
Regarding Marijuana Enforcement.”48 This memorandum shifted 
governmental priorities from tough enforcement of federal cannabis law 
towards a more hands-off approach in those “jurisdictions that have 
enacted laws legalizing marijuana in some form and that have also 
implemented strong and effective regulatory and enforcement systems 
to control the cultivation, distribution, sale and possession of 
marijuana.”49 Further, the Cole Memorandum declared that: 
a robust system may affirmatively address [federal] priorities by, 
for example, implementing effective measures to prevent diversion 
of marijuana outside the regulated system and to other states, 
prohibiting access to marijuana by minors, and replacing an illicit 
marijuana trade that funds criminal enterprises with a tightly 
regulated market in which revenues are tracked and accounted 
for.50 
The relaxed attitude of the Obama Administration did not survive 
past the first year of the Trump presidency. On January 4, 2018, 
Attorney General Jefferson B. Sessions, III drafted a memorandum to 
all U.S. Attorneys rescinding the Cole Memorandum and other federal 
guidelines that circumscribed the prosecution of individuals and entities 
following state law in the use and sale of marijuana.51 Federal 
prosecutors have been instructed to decide which cases to prosecute 
based on “federal law enforcement priorities set by the Attorney 
General, the seriousness of the crime, the deterrent effect of the criminal 
prosecution, and the cumulative impact of particular crimes of the 
community.”52 
B.  State Marijuana Law 
According to the National Conference of State Legislatures, as of 
2018, thirty-three states plus the District of Columbia, Guam, and 
Puerto Rico have enacted laws permitting the medical use of 
 
48. DEPUTY ATT’Y GEN. JAMES M. COLE, MEMORANDUM FOR ALL UNITED 
STATES ATTORNEYS: GUIDANCE REGARDING MARIJUANA ENFORCEMENT, 
Aug. 29, 2013), available at https://www.justice.gov/iso/opa/ 
resources/3052013829132756857467.pdf. 
49. Id. 
50. Id. 
51. Id. 
52. Id. 
Health Matrix·Volume 29·Issue 1·2019 
High Times Ahead:  Products Liability in Medical Marijuana 
234 
marijuana.53 States that have legalized medical marijuana are 
predominantly in the west, southwest, northeast, and northwest.54 
The Arizona Medical Marijuana Act (AMMA), captioned as A.R.S. 
§§ 36-2801 to -2819, was passed as Proposition 203 in 2010.55 The law 
permits the certification of individuals with a “debilitating medical 
condition” for medical marijuana use.56 Debilitating conditions include 
the following: 
(a) Cancer, glaucoma, positive status for human 
immunodeficiency virus (HIV), acquired immune deficiency 
syndrome (AIDS), hepatitis C, amyotrophic lateral sclerosis, 
crohn’s disease, agitation of alzheimer’s disease or the treatment 
of these conditions.57 
(b) A chronic or debilitating disease or medical condition or its 
treatment that produces one or more of the following: cachexia or 
wasting syndrome; severe and chronic pain; severe nausea; 
seizures, including those characteristic of epilepsy; or severe and 
persistent muscle spasms, including those characteristic of 
multiple sclerosis. 
(c) Any other medical condition or its treatment added by the 
department pursuant to section 36-2801.01.58 
Qualifying patients are certified for medical use of marijuana by 
actively licensed allopathic, osteopathic, naturopathic, or homeopathic 
physicians in Arizona.59 Physicians do not “prescribe” marijuana 
because that would violate federal law.60 Instead, physicians 
 
53. Jeremy Berke & Skye Gould, This Map Shows Every US State Where Pot 
is Legal, BUS. INSIDER (Jan. 4, 2019), https://www.businessinsider.com 
/legal-marijuana-states-2018-1. 
54. See Marijuana DeepDive, NAT’L CONF. ST. LEGIS., http://www.ncsl.org 
/bookstore/state-legislatures- magazine/marijuana-deep-dive.aspx (last 
visited Jan. 27, 2018). 
55. Ariz. Rev. Stat. Ann. § 36-2801(18) (2010). 
56. Id. 
57. The Arizona legislature left out the capital letters of the diseases 
characterized by and named after Alois Alzheimer, M.D. and Burrill 
Crohn, M.D. Ariz. Rev. Stat. Ann. § 36-2801(3) (2010). 
58. Debilitating conditions are subject to change annually via petition to the 
state health department. Id.; See e.g., Petition to Add a Debilitating 
Condition, COLO. DEP’T PUB. HEALTH & ENV’T, https:// 
www.colorado.gov/pacific/cdphe/petition-to-add-debilitating-condition 
(last visited Dec. 18, 2018). 
59. Ariz. Rev. Stat. Ann. §§ 36-2801(12), (13) (2018). 
60. TODD GARVEY ET AL., CONG. RESEARCH SERV., R43435, MARIJUANA: 
MEDICAL AND RETAIL – SELECTED LEGAL ISSUES at 4 (2015). 
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“recommend” marijuana and certify in writing that they believe the 
patient is likely to “receive therapeutic or palliative benefit from the 
medical use of marijuana to treat or alleviate the patient’s debilitating 
medical condition or symptoms associated with the debilitating 
condition.”61 The physician’s right to recommend marijuana has been 
held to be protected by the First Amendment.62 
III. Medical Marijuana as a “Pharma-pseudical”   
States considering the legalization of medical marijuana must 
consider the paradigm under which it will be regulated. This is 
complicated by the fact that, in many ways, medical marijuana is a 
unique product because it is used for both recreation and medical 
purposes. Medical cannabis is “recommended” by doctors, but never 
prescribed. It is rarely dispensed by a pharmacist, but rather by a 
retailer with no mandatory training or certification.63 Thus, medical 
cannabis has some characteristics in common with alcohol, tobacco, 
nutritional supplements, and pharmaceuticals. Medical marijuana most 
closely resembles a pharmaceutical; though important differences exist. 
For that reason, the term, “pharma-pseudical,” shall be used to indicate 
medical marijuana is akin to a pseudo-pharmaceutical. 
A. Alcohol 
Although there are similarities, there are three reasons why alcohol 
is not a useful heuristic for marijuana regulation. First, while alcohol 
and marijuana have intoxicating effects with oral or intravenous 
administration, there is no currently recognized medical indication for 
the internal use of alcohol.64 Once used internally as an anesthetic and 
 
61. Ariz. Rev. Stat. Ann. § 36-2801(12). 
62. Conant v. Walters, 309 F.3d 629, 638-39 (9th Cir. 2002) (affirming district 
court’s permanent injunction enjoining federal government from revoking 
DEA registration or investigating physician in a manner that might lead 
to revocation where the government’s action based solely on physician’s 
recommendation of medical marijuana. Doctor’s speech to patient 
protected under First Amendment). 
63. State Medical Marijuana Legislation and the Pharmacist’s Role, NAT’L 
CMTY. PHARMACISTS ASS’N, http://www.ncpa.co/pdf/medical-marijuana-
one-pager-aug-2017.pdf (last visited Dec. 18, 2018). 
64. Alcohol, If You Drink it, Keep it Moderate, MAYO CLINIC, 
https://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-
eating/in-depth/alcohol/art-20044551 (last updated Nov. 6, 2018); 
Resveratrol, a component of the skins of red grapes has a limited 
antioxidant and anti-inflammatory effect. Evidence of its benefits is 
minimal. Chandra K. Sing, et al., Resveratrol, in its Natural Combination 
in Whole Grape, for Health Promotion and Disease Management, 1348 
ANNALS N.Y. ACAD. SCI. 150, 151 (2015). 
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as a tocolytic in the mid-twentieth century, 65 alcohol is currently 
indicated only externally as an antiseptic and disinfectant.66 
Second, ethyl alcohol is regulated by a complex network of federal, 
state, and municipal statutes and rules.67 Medical marijuana is 
regulated by state law68 and issues of zoning are municipal.69 Third, 
because the dangers of alcohol are readily apparent and universally 
known, manufacturers of alcoholic beverages have a very limited duty 
to warn consumers.70 Beverages containing more than 0.5% of alcohol 
by volume are required to have only two warnings: “(1) According to 
the Surgeon General, women should not drink alcoholic beverages 
during pregnancy because of the risk of birth defects. (2) Consumption 
 
65. Tocolytic drugs are used to stop preterm labor. The current drug of choice 
is terbutaline. J.D. Whitby, Alcohol in Anaesthesia and Surgical 
Resuscitation, 35 ANAESTHESIA 502, 502 (1980); Marc J.N.C. Keirse, The 
History of Tocolysis, 110 BRITISH J. OBSTETRICS AND GYNAECOLOGY 94, 
95 (2003). 
66. Ethyl alcohol has been taken internally; isopropyl alcohol is used 
externally. See Gerald McDonnell & A. Denver Russell, Antiseptics and 
Disinfectants: Activity, Action, and Resistance, 12 CLINICAL 
MICROBIOLOGY REV. 147, 148-151 (1999). 
67. See e.g., 26 U.S.C. §5601(a)(8) (2006); VA. CODE ANN. §§ 4.1-100, 4.1-
302; LAKEWOOD, COLO. MUN. CODE § 9.41.070 (2015). 
68. See Gina K. Grimes & Morris C. Massey, Medical Marijuana – 
Differences Among States’ Regulatory Frameworks and Land Use and 
Zoning Regulation, 29 PROBATE & PROPERTY MAGAZINE (Nov. 2015), 
available at https://www.americanbar.org/groups/real_property_trust_ 
estate/publications/probate_property_magazine_home/2015/november
_de 
cember_2015/2015_aba_rpte_pp_v29_6_article_grimes_massey_me
dical_marijuana_differences_among_states.html. 
69. Robert Careless, Zoning Hurdles for Budding Pennsylvania Cannabis 
Businesses, THE TEMPLE 10-Q (Oct. 27, 2017), https://www2.law. 
temple.edu/10q/zoning-hurdles-budding-pennsylvania-cannabis-
businesses/. 
70. After Abernathy died of acute alcohol intoxication, his estate sued 
whiskey distiller, Schenley, for failure to warn of the hazards of acute 
intoxication. The Fourth Circuit Court of Appeals held that fulfilling the 
statutory labeling obligations was sufficient to eschew liability. See 
Abernathy v. Schenley Industries, Inc., 556 F.2d 242, 243 (4th Cir. 1977) 
(holding that fulfilling statutory labeling obligations was sufficient to 
eschew liability). Garrison sued Heublein, manufacturer and distributor 
of Smirnoff Vodka, under a failure to warn theory for mental and physical 
injuries arising from two decades of heavy vodka consumption. Adopting 
Restatement (Second) of Torts § 402A as Illinois law, the court dismissed 
the case, holding that the dangers of alcohol were common knowledge, 
and the product was not unreasonably unsafe. See Garrison v. Heublein, 
Inc., 673 F.2d 189 (7th Cir. 1982). 
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of alcoholic beverages impairs your ability to drive a car or operate 
machinery, and may cause health problems.” 71 
B. Tobacco 
Tobacco is also a poor choice as a paradigm for medical marijuana 
regulation. Tobacco has no recognized medicinal use.72 It is permitted, 
but regulated by numerous federal, state, and local laws.73 Marijuana is 
not regulated by any federal laws, only prohibited.74 Severe, adverse 
health effects are widely recognized, in part due to the ubiquitous 
warning labels on each cigarette pack.75 Since 1984, cigarette 
manufacturers have been required to display on each pack of cigarettes 
one of four health warning labels on a quarterly rotating basis:76 
 
 
Figure 2. Cigarette Warning Labels 
C. Nutritional Supplements 
Nutritional supplements and medical marijuana are both promoted 
for their salutary effects,77 although compelling scientific evidence of the 
 
71. 27 C.F.R. § 16.21 (1990). 
72. John Harvey Kellog, Tobaccoism, 92 AM. J. PUB. HEALTH 932, 932 (2002). 
73. Local Tobacco Regulation, RJREYNOLDS, https://www.rjrt.com/ 
commercial-integrity/state-local-regulation/ (last visited Sept. 21, 2018). 
74. Donna Leinwand Leger, Marijuana to Remain Illegal Under Federal Law, 
DEA Says, USA TODAY (Aug. 11, 2016, 5:54 PM), 
https://www.usatoday.com/story/news/2016/08/11/dea-marijuana-
remains-illegal-under-federal-law/88550804/. 
75. 15 U.S.C. § 1333(a)(1) (2010). 
76. Making Decisions Regarding Tobacco Use, RJREYNOLDS, 
http://www.rjrt.com/tobacco-use-health/public-health-information/ 
(last visited Oct. 14, 2018). 
77. Dietary Supplements: What you Need to Know, NIH - NAT’L INST. 
HEALTH, 
https://ods.od.nih.gov/HealthInformation/DS_WhatYouNeedToKnow.a
spx (last updated June 17, 2011); Peter Grinspoon, Medical Marijuana, 
HARV. HEALTH PUB. (Jan. 15, 2018), https://www.health.harvard.edu 
/blog/medical- marijuana-2018011513085. 
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benefits of supplements is lacking.78 Supplements are federally regulated 
by the Food and Drug Administration (FDA) under the Dietary 
Supplement Health and Education Act of 1994;79 however, the FDA 
does not evaluate dietary supplements for effectiveness and safety in 
the premarketing phase.80 The FDA is only authorized to restrict the 
sale of misbranded or adulterated dietary supplements in the 
marketplace.81 
While the FDA does not currently regulate medical marijuana, that 
may change soon. On October 3, 2017, the FDA Commissioner, Scott 
Gottlieb, indicated that the agency would investigate dubious health 
claims made by marijuana producers, especially anti-tumor/anti-cancer 
effects of THC.82 
With rare exceptions, dietary supplements have no psychoactive 
effects and are not recommended for the treatment of any condition or 
disease in traditional modern medicine.83 Most supplements are required 
to have a disclaimer that any claims of benefit have not been evaluated 
by the FDA.84 They may be recommended by some physicians, 
especially those practicing alternative medicine, but prescriptions and 
certifications are not required.85 
D. Pharmaceuticals 
Medical marijuana is most closely related to pharmaceuticals. 
Cannabis has specific medical indications defined by statute while 
 
78. Should You Take Dietary Supplements?, NIH NEWS IN HEALTH (Aug. 
2013), https://newsinhealth.nih.gov/2013/08/should-you-take-dietary-
supplements. 
79. Dietary Supplements, U.S. FOOD & DRUG ADMIN., https://www.fda.gov 
/food/dietarysupplements/ (last updated Nov. 16, 2018). 
80. See Id. 
81. Id. 
82. FDA and Marijuana, U.S. FOOD & DRUG ADMIN., https://www.fda.gov 
/NewsEvents/PublicHealthFocus/ucm421163.htm (last updated June 25, 
2018). 
83. NIH NEWS IN HEALTH, supra note 78. 
84. Understanding the Claims on Dietary Supplement Labels, AM. CANCER 
SOC., https://www.cancer.org/treatment/treatments-and-side-effects/ 
complementary-and-alternative-medicine/dietary-supplements/reading-
labels.html (last updated Mar. 31, 2015); Questions and Answers on 
Dietary Supplements, U.S. FOOD & DRUG ADMIN., https://www. 
fda.gov/Food/DietarySupplements/UsingDietarySupplements/ucm48006
9.htm. (last updated Jun. 19, 2018). 
85. Where Can I Purchase Dietary Supplements?, NAT’L INST. HEALTH, 
https://ods.od.nih.gov/Health_Information/ODS_Frequently_Asked_
Questions.aspx, (last updated July 1, 2013). 
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medications have specific medical indications defined by the FDA.86 A 
patient can only obtain medical cannabis if it has been recommended 
by a physician and can only obtain many pharmaceuticals if they have 
been prescribed by a physician. Prior to patient certification for medical 
cannabis, in some states a physician must perform a medical history 
and physical examination, review prior medical records, and weigh the 
risks and benefits of medical marijuana for the particular patient.87 This 
process closely resembles traditional medical practice with 
pharmaceuticals. 
Perhaps, the most persuasive reason for comparing medical 
marijuana and pharmaceuticals is that plant-derived THC is identical 
to the drug, Marinol (dronabinol).88 Marinol is a synthetic version of 
THC,89 with important similarities. Marinol is a Schedule III90 
controlled substance indicated for the treatment of AIDS-related 
anorexia associated with weight loss, as well as chemotherapy-induced 
nausea and vomiting when standard antiemetics are ineffective.91 
Marinol users are warned against operating a motor vehicle and heavy 
machinery or engaging in other hazardous activities.92 Oral dosages 
range from 2.5 milligrams to 20.0 milligrams per day.93 Multiple drug 
interactions have been reported, most commonly with antidepressants, 
antihistamines, benzodiazepines, and barbiturates.94 
From the products liability perspective, one of the most important 
questions is whether the Learned Intermediary Doctrine will apply to 
medical cannabis as it does to pharmaceuticals. If the doctrine applies 
to both, much of the liability from harm related to medical marijuana 
will be redirected from the participants in the supply chain to the 
physicians. 
 
86. Omudhome Ogbru, Indications for Drugs (Uses), Approved vs. Non-
Approved, MEDICINENET (Aug. 20, 2015), https://www. 
medicinenet.com/indications_for_drugs__approved_vs_non-
approved/views.htm. 
87. The Role of the Physician in “Medical” Marijuana, AM. SOC’Y ADDICTION 
MED. 20-21 (2010), available at https://www.asam.org/docs/publicy-
policy-statements/1role_of_phys_in_med_mj_9-10.pdf?sfvrsn=0. 
88. U.S. FOOD & DRUG ADMIN., NDA 18-651/S-021, MARINOL (2004). 
89. ALISON MACK & JANET JOY, MARIJUANA AS MEDICINE? 142 (2001). 
90. A Schedule III drug has “a moderate to low potential for physical and 
psychological dependence.” Drug Scheduling, supra note 42. 
91. MACK & JOY, supra note 89 at 8. 
92. FOOD & DRUG ADMIN., REFERENCE ID: 4145204, FULL PRESCRIBING 
INFORMATION: MARINOL (2017). 
93. U.S. FOOD & DRUG ADMIN., NDA 18-651/S-025 AND S-026, MARINOL 
(2004). 
94. Id. 
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The Learned Intermediary Doctrine limits a manufacturer’s duty 
to warn about the potential adverse consequences of a pharmaceutical 
or medical device to the prescribing physician and not the patient.95 For 
example, in Toole v. McClintock, the adequacy of the manufacturer’s 
warning about the hazards of its breast implant was based solely on the 
efficacy of the warning to the patient’s physician.96 The court held that 
the manufacturer had no duty to warn the patient.97 
Notwithstanding the Learned Intermediary Doctrine, some courts 
have implicitly or explicitly held that a manufacturer has a duty to 
directly warn patients of the potential hazards of their drugs or medical 
devices.98 Three exceptions to the Doctrine have been carved out: (1) 
warnings to parents of minor children;99 (2) direct marketing of drugs 
to consumers;100 and (3) treatment decisions driven predominantly by 
patient choice with minimal physician input.101 
The applicability of the Learned Intermediary Doctrine to medical 
cannabis is uncertain. The following reasons illustrate why it is likely 
that the Learned Intermediary Doctrine will not apply and participants 
in the cannabis supply chain will bear the majority of the liability for 
harms suffered by patients. Most medical marijuana evaluations are 
performed at “specialty” medical marijuana clinics that have only one 
purpose - to ascertain whether a patient is a suitable candidate for 
 
95. Hill v. Wyeth, Inc., No. 4:03CV1526 JCH, 2007 WL 674251 (E.D. Mo. 
Feb. 28, 2007). 
96. Toole v. McClintock, 999 F.2d 1430, 1436 (11th Cir. 1993). 
97. Id. at 1433. 
98. See e.g., Reyes v. Wyeth Lab., 498 F.2d 1264, 1274 (5th Cir. 1974); Perez 
v. Wyeth Lab., 734 A.2d 1245, 1247 (N.J. 1999); McDonald v. Ortho 
Pharm. Co., 475 N.E.2d 65, 68 (Mass. 1985). 
99. Reyes v. Wyeth Laboratories, 498 F.2d 1264, 1279 (5th Cir. 1974). 
100. In a case involving the subdermal insertion of the contraceptive, Norplant, 
the Supreme Court of New Jersey opined “that the learned intermediary 
doctrine does not apply to the direct marketing of drugs to consumers 
. . . .” Perez v. Wyeth Laboratories, 734 A.2d 1245, 1257 (N.J. Sup. Ct. 
1999). Plaintiffs argued that Norplant was advertised directly to women, 
not to doctors, but did not warn consumers of the potential dangers. The 
Court held that Defendant cannot engage in deceptive advertising and 
they had a duty to warn. 
101. In MacDonald v. Ortho Pharmaceutical Corp., the Massachusetts 
Supreme Court concluded that, due to the significant participation of the 
patient in birth control pill decisions, the limited participation of doctors, 
the ease of making direct warnings to patients, and the considerable risks 
of the medication, the manufacturer had a duty to provide warnings 
directly to the patients and could not simply rely on warnings made to 
their doctors. MacDonald v. Ortho Pharm. Corp., 475 N.E.2d 65, 70 
(Mass. 1985). 
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medical marijuana.102 The medical history and physical exam focuses on 
whether the patient has (or might have) a certifiable condition.103 
Laboratory testing is not required and no other medications are 
prescribed.104 Doctors may perform evaluations as frequently as every 
fifteen minutes105 and clinics may be open six or seven days per week.106 
Clinics advertise heavily on the internet and in print.107 Facilities may 
even waive the evaluation fee if the doctor cannot certify the patient 
for medical marijuana.108 The physicians working in medical marijuana 
clinics, predominantly naturopathic physicians,109 have no special 
medical training in the pharmacology or prescribing of medical 
cannabis.110 Because medical cannabis is not regulated by the federal 
government like a prescription drug, cannabis manufacturers are not 
required to provide health care providers with continuing education, 
product information, dosing instructions, warnings, or 
 
102. Kevin P. Hill, Medical Marijuana for the Treatment of Chronic Pain and 
Other Psychiatric Problems: A Clinical Review, 313 J. AM. MED. ASS’N 
2474 (2015). 
103. What to Expect, CANNA-CENTERS, https://www.canna-centers.com/what-
to-expect/ (last visited Sep. 22, 2018). 
104. See Dianne Cochrane, Marijuana Card: Medical Marijuana OK’d After 8 
Minutes, 6 Questions, BILLINGS GAZETTE (Aug. 21, 2010), 
https://billingsgazette.com/news/local/medical-marijuana-card-ok-d-
after-minutes-questions/article_873a0ad2-adaf-11df- 8799-
001cc4c002e0.html; Melissa Sherrard, What to Expect When You Visit a 
Medical Marijuana Doctor, CIVILIZED (June 5, 2017), 
https://www.civilized.life/articles/what-to-expect-when-you-visit-the-
medical-marijuana-doctor/. 
105. See, e.g., Frequently Asked Questions, SW. MEDICAL MARIJUANA 
EVALUATION CTR., http://www.evaluationtoday.com/medical_marijuana 
_faqs.html (last visited Jan. 10, 2019). 
106. See, e.g., ARIZ. GREEN LIFE, https://azgreenlife.com/ (last visited Jan. 
10, 2019). 
107. Eli McVey, Chart: Most Effective Forms of Advertising for Cannabis 
Businesses, MARIJUANA BUS. DAILY (Nov. 12, 2017), 
https://mjbizdaily.com/wp-content/uploads/2017/11/11-13-17-
COTW.png. 
108. MEDICAL MARIJUANA TREATMENT CLINICS FLA., 
https://www.mmtcfl.com / (last visited Jan. 11, 2019). 
109. Medical Marijuana Annual Report A.R.S. §36-2809, ARIZ. DEP’T. 
HEALTH SERV. 26 (Jan. 14, 2016), https://www.azdhs.gov/documents 
/licensing/medical-marijuana/reports/2015/2015-mm-annual-report-
160114.pdf. 
110. ARIZ. DEP’T HEALTH SERV., ADHS12-017291, MEDICAL MARIJUANA 
ANNUAL REPORT A.R.S. § 36-2809 (Jan. 14, 2016), available at 
https://www.azdhs.gov/documents/licensing/medical-marijuana/reports 
/2015/2015-mm-annual-report-160114.pdf. 
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contraindications.111 Dispensaries provide limited information and most 
patients are left to educate themselves. 
In summary, medical marijuana is a pharma-pseudical, dispensed 
in a manner that circumvents the Learned Intermediary Doctrine, 
similar to birth control medication,112 because: (1) the product is heavily 
marketed directly to consumers; (2) patients take a very prominent role 
in the decision to use the medication; and (3) the role of the physician 
is less significant in comparison to other therapeutic decisions. 
Participants in the medical marijuana supply chain have a duty to 
warn, which must be directed at the patient rather than the physician. 
IV. Health Effects of Cannabis & Cannabinoids  
A. Beneficial Effects of Cannabinoids 
Cannabis is an old remedy. Written records of cannabis use date 
back to the sixth century B.C.E.113 Cannabis was introduced to Western 
medicine in the mid-1800’s and was included in the Third Edition of 
the United States Pharmacopeia in 1851.114 It was used as an analgesic, 
anticonvulsant, and sedative-hypnotic until its sale and distribution 
became illegal under federal law in 1937.115 In 1996, cannabis became 
legal for medicinal purposes in California.116 Because medical marijuana 
is still illegal under federal law, research into the benefits and risks of 
its administration has been sharply circumscribed in the United 
States.117 For example, in a letter to Congressman Tim Walz, 
Department of Veterans Affairs Secretary David Shulkin wrote, “VA is 
committed to researching and developing effective ways to help 
Veterans cope with post-traumatic stress disorder and chronic pain 
conditions . . . [h]owever, federal law restricts VA’s ability to conduct 
 
111. See PLR Requirements for Prescribing Information, U.S. FOOD & DRUG 
ADMIN., 
https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/l
awsactsandrules/ucm084159.htm (last updated Dec. 4, 2019). 
112. Supra note Part VII. 
113. Ethan B. Russo, History of Cannabis and its Preparations in Saga, 
Science, and Sobriquet, 4 CHEMISTRY & BIODIVERSITY 1614, 1625-26 
(2007). 
114. NAT’L ACAD. SCIENCES, ENG’G, & MED., supra note 11, at 43. 
115. Kaloyan Ivanov, High Times: The Evolution of the Stigma on Marijuana 
and Attempts to Tear it Down, 13 EUKARYON 61 (2017). 
116. NAT’L ACAD. OF SCI., ENG’G, & MED., supra note 11, at 67-68. 
117. Sarah See Stith & Jacob Miguel Virgil, Federal Barriers to Cannabis 
Research, 332 SCIENCE 1182, 1182 (2016). 
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research involving medical marijuana, or to refer veterans to such 
projects.”118 
Cannabis appears to be an effective treatment for the reduction of 
chronic pain, especially neuropathic pain.119 In a review of five “high-
quality randomized controlled clinical trials,” each demonstrated the 
analgesic effects of smoked cannabis.120 In a meta-analysis of twenty-
eight placebo-controlled studies using predominantly plant-derived 
cannabinoids, Whiting found that the odds of improvement in pain 
control in the cannabis group increased by thirty percent, and the effect 
was dose-dependent.121 Chronic pain was mostly neuropathic but other 
etiologies were included.122 A study of 244 chronic pain patients 
determined that medical cannabis use was associated with a sixty-four 
percent reduction in opioid use, fewer side effects, and a forty-five 
percent improved quality of life.123 
The efficacy of cannabis as a treatment for cancer is speculative as 
there is insufficient primary research to suggest a therapeutic benefit.124 
However, there is conclusive evidence that cancer chemotherapy-
induced nausea and vomiting can effectively be treated by oral 
cannabinoids as antiemetics.125 Cannabinoids with high THC-
concentrations were comparable to standard antiemetics in efficacy, but 
combinations of the two drugs were non-synergistic.126 High CBD 
preparations have not been tested for treatment of chemotherapy-
induced emesis.127 
Anorexia and weight loss contribute to the morbidity and mortality 
of numerous diseases and cannabis is moderately beneficial in averting 
 
118. Katie Zezima, VA Says it Won’t Study Medical Marijuana’s Effect on 
Veterans, WASH. POST (Jan. 16, 2018), https://www.washingtonpost.com 
/news/post-nation/wp/2018/01/16/va-says-it-wont-study-medical-
marijuanas-effect-on- veterans/. 
119. Seddon R. Savage et al., Cannabis in Pain Treatment: Clinical & 
Research Considerations. 17 J. PAIN 654, 662 (2016). 
120. Id. at 657. 
121. Penny Whiting et al., Cannabinoids for Medical Use: A Systematic 
Review and Metanalysis, 313 J. AM. MED. ASS’N 2456, 2460 (2018). 
122. The other conditions included cancer pain, multiple sclerosis, rheumatoid 
arthritis, musculoskeletal issues, and chemotherapy-induced pain. Id. 
123. Kevin F. Boehnke et al., Medical Cannabis Use is Associated with 
Decreased Opiate Medication Use in a Retrospective Cross- Sectional 
Survey of Patients with Chronic Pain, 17 J. PAIN 739, 741 (2016). 
124. NAT’L ACAD. SCIENCES, ENG’G, & MED., supra note 11, at 91. 
125. Whiting et al., supra note 121, at 2459. 
126. Id. at 2469. 
127. See id. 
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those effects.128 Two out of three studies showed some improvement in 
appetite in cancer patients.129 In women with anorexia nervosa, low dose 
THC was associated with weight gain despite no change in the 
psychopathology of the eating disorder itself.130 
An Israeli group reported on the treatment of seventy-four children 
and adolescents with cannabis for intractable epilepsy.131 Although 
ethical considerations precluded the use of a control group, the results 
were dramatic. Eighteen percent of the subjects experienced a 75-100% 
reduction in seizures; thirty-four percent had a fifty to seventy-five 
percent reduction in seizures; twelve percent had a twenty-five to fifty 
percent reduction in seizures; and twenty-six percent had less than a 
twenty-five percent reduction in seizures.132 
Medical marijuana has been advocated for treatment of spasticity 
associated with multiple sclerosis and spinal cord injury.133 Multiple 
reviews have concluded that oral cannabis is probably effective for 
reducing spasticity in multiple sclerosis, but there was insufficient 
evidence to support its efficacy in spinal cord injuries.134 In patients 
with tics from Tourette’s syndrome, oral THC was effective in reducing 
tic frequency.135 However, cannabis was of no benefit for Amyotrophic 
Lateral Sclerosis (ALS) or for the choreiform movements of 
Huntington’s Disease.136 
CBD capsules were found to improve the quality of life in a twenty-
one-patient randomized, double-blind, placebo-controlled study of 
 
128. Jeffrey E. Beal et al., Dronabinol as a Treatment for Anorexia Associated 
with Weight Loss in Patients with AIDS, 10 J. PAIN SYMPTOM MGMT. 89, 
89 (1995). 
129. ESLEY A. SMITH ET AL., CANNABINOIDS FOR NAUSEA AND VOMITING IN 
ADULTS WITH CANCER RECEIVING CHEMOTHERAPY 14 (2015). 
130. Alin Andries et al., Dronabinol in Severe, Enduring Anorexia Nervosa: A 
Randomized Controlled Trial, 47 INT. J. EATING DISORDERS 18, 22 (2014). 
131. Intractable epilepsy is a seizure disorder in which a patient’s seizures are 
not controlled with treatment. These seizures are also referred to as 
“refractory.” Michal Tzadok et al, CBD-Enriched Medical Cannabis for 
Intractable Pediatric Epilepsy: The Current Israeli Experience, 35 
SEIZURE: EUROPEAN JOURNAL OF EPILEPSY 41, 41 (2016). 
132. Id. 
133. NAT’L ACAD. SCIENCES, ENG’G, & MED, supra note 11, at 2463. 
134. Id. at 103. 
135. K.R. Müller-Vahl et al., Influence of Treatment of Tourette Syndrome 
with D9-Tetrahydrocannabinol (D9-THC) on Neuropsychological 
Performance, 34 PHARMACOPSYCHIATRY 19, 19 (2001). 
136. NAT’L ACAD. SCIENCES, ENG’G, & MED, supra note 11, at 106. 
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Parkinson’s disease.137 Smoked cannabis also showed a statistically 
significant improvement in Parkinsonian rigidity, tremor, and 
bradykinesia in a similar study.138 No therapeutic effect from cannabis 
was evident in dementia.139 
Although cannabis lowers intraocular pressure for two hours,140 it is 
ineffective for the treatment of glaucoma.141 Patients with traumatic 
brain injury or intracranial hemorrhage had better outcomes with 
cannabis use.142 Individuals with social anxiety disorder were benefitted 
by cannabis use.143 Depression was unresponsive to cannabis; however, 
cannabinoids improved short-term sleep in patients with pathological 
sleep disturbances, including fibromyalgia, sleep apnea, and chronic 
pain.144 
Psychological disorders also vary in their responsiveness. 
Randomized trials are underway to assess the potential benefits of 
cannabis in post-traumatic stress disorder (PTSD).145 One study of male 
Canadian soldiers with PTSD showed a considerable reduction in 
nightmares and an improvement in general well-being with oral THC 
treatment.146 Cannabis showed no benefit in patients with schizophrenia 
or other psychoses.147 
The limited research conducted with medical cannabis has 
produced positive results in a variety of diagnoses; however, more 
research is needed to evaluate symptom relief and monitor outcomes. 
 
137. Marcos Hortes N. Chagas et al., Effects of Cannabidiol in the Treatment 
of Patients with Parkinson’s Disease: An Exploratory Double-Blind Trial, 
28 J. PSYCHOPHARAMCOLOGY 1088, 1090 (2014). 
138. Itay Lotan et el., Cannabis (Medical Marijuana) Treatment for Motor 
and Non-Motor Symptoms of Parkinson Disease: An Open-Label 
Observational Study, 37 CLINICAL NEUROPHARMACOLOGY 41, 42 (2014). 
139. S. KRISHNAN, ET AL., CANNABINOIDS FOR THE TREATMENT OF DEMENTIA 8 
(2009). 
140. Ileana Tomida et al., Effect of Sublingual Application of Cannabinoids on 
Intraocular Pressure: A Pilot Study, 15 J. GLAUCOMA 349 (2006). 
141. Whiting et al., supra note 121, at 2464. 
142. NAT’L ACAD. SCIENCES, supra note 11, at 116. 
143. Whiting et al., supra note 121, at 2463. 
144. Id. at 2464. 
145. Rakesh Jetly et al., The Efficacy of Nabilone, A Synthetic Cannabinoid, 
in the Treatment of PTSD-Associated Nightmares: A Preliminary 
Randomized, Double-Blind, Placebo-Controlled Cross-Over Design Study, 
51 PSYCHONEUROENDOCRINOLOGY 585, 587 (2015). 
146. Id. 
147. See BENJAMIN C. MCLOUGHLIN ET AL., CANNABIS AND SCHIZOPHRENIA 3 
(2014). 
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B. Adverse Effects of Cannabinoids 
Medical cannabis has produced adverse reactions in certain disease 
states and in specific groups of patients. Increased risk of acute 
myocardial infarction was not found in cannabis users, but limited 
evidence suggested that cannabis use could acutely trigger a myocardial 
infarction or an ischemic stroke.148 Inhalation of cannabis smoke by 
individuals with pre-existing angina reduces the amount of exercise 
required to precipitate an angina attack by fifty percent and has been 
associated with a “five-fold increase[d] risk of Myocardial 
Infarctions . . . in the first hour after” smoking.149 
No statistically significant association was found between smoking 
cannabis and lung cancer,150 head and neck cancers,151 esophageal 
cancers,152 or other cancers except for non-seminoma type testicular 
cancer.153 Cannabis smoke, however, does contain many of the same 
compounds as tobacco smoke.154 There is strong evidence that cannabis 
smoke is not only carcinogenic, but also potentially more cytotoxic and 
mutagenic than cigarette smoke.155 Cannabis smokers retain three times 
the level of tar and five times the level of carbon monoxide in their 
lungs compared with tobacco smokers.156 Cannabis smokers also inhale 
twenty times the level of ammonia and up to five times the level of 
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hydrogen cyanide as tobacco smokers.157 Habitual smoking of cannabis 
is associated with a higher incidence of wheezing, coughing, and phlegm 
production as well as an increased risk of developing or exacerbating 
chronic obstructive pulmonary disease.158 Cessation of cannabis smoking 
or switching to a vaporizer diminished these symptoms.159 
Driving impairment occurs early in occasional cannabis users and 
requires a THC blood level of just 2-5 ng/ml.160 Smoking or vaporizing 
ten milligrams of THC yielded blood levels at or above 5 ng/mL within 
ten minutes.161 Consuming a fifteen-milligram edible produced the same 
blood level in two to four hours.162 In other words, occasional cannabis 
users become impaired early and often. Not surprisingly, cannabis use 
is substantially linked to an increased risk of motor vehicle accidents 
and a higher blood THC level correlates with an increased likelihood of 
an accident.163 It takes six to eight hours for the impairment to 
resolve.164 Combined use of cannabis and alcohol increases accident risk 
more than either substance alone.165 
Deaths related to cannabis use are extremely uncommon,166 
however, among the pediatric population, cannabis exposure was 
related to CNS and respiratory depression.167 Physicians in Colorado 
conducted a retrospective analysis of children under age twelve who 
were evaluated at the emergency room of a tertiary care children’s 
hospital in Colorado.168 Prior to legalization, no pediatric cases of  
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cannabis overdose occurred; post-legalization, there were fourteen 
confirmed cases within a two-year period.169 Of the eight patients 
admitted to hospital, two required admission to the intensive care 
unit.170 Seven of the eight exposures were from edibles,171 likely because 
they often look like and taste like regular candies, soft drinks, and baked 
goods.172 
Compared with adults, the effects of pediatric cannabis intoxication 
are more pronounced and occur at lower doses.173 Common symptoms 
include ataxia, somnolence, lethargy, altered mental status, and 
obtundation (reduced alertness).174 Rarely, children will present with 
severe symptoms, such as apnea, cyanosis (discoloration of skin), 
bradycardia (slowed heart rate), hypotonia (decreased muscle tone), 
and opisthotonus (severe hyperextension and spasticity).175 
The Committee on Obstetric Practice of the American College of 
Obstetrics and Gynecology reviewed the effects of marijuana use during 
pregnancy and lactation.176 Children exposed to marijuana in utero 
achieved lower scores on visual problem solving, visual-motor 
coordination, and visual analysis tasks.177 Reduced attention spans and 
increased behavioral problems were evident.178 Newborns exposed to 
cannabis in utero had shorter birth lengths, lower birth weights, and 
smaller head circumferences, all of which correlated with the amount of 
maternal marijuana use during the first and second trimesters of 
pregnancy.179 This committee recommended counseling pregnant 
women about the potential adverse health consequences of cannabis use 
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during pregnancy.180 Because cannabinoids are found in breast milk, 
they also advised lactating women to discontinue marijuana use.181 
A study of 975 individuals in upstate New York to assess whether 
cannabis use over an eight-year period during childhood, adolescence, 
and the early twenties was predictive of neurocognitive and behavioral 
problems in the late twenties.182 The study, which was controlled for 
age, gender, income, and other mental disorders, clearly demonstrated 
that marijuana use was predictive of later health problems.183 Cannabis 
users were thirty-six percent more likely to have neurocognitive 
problems, twenty-six percent more likely to have lower academic 
functioning and achievement, and fifty-two percent more likely to have 
general malaise.184 The researchers hypothesized that “neurocognitive 
impairment may be a mechanism that mediates the association between 
marijuana use and lower academic achievement and functioning.”185 
The results of studies on the effects of marijuana use by adolescents 
and young adults have been reported by the Colorado Retail Marijuana 
Public Health Advisory Committee (Colorado Retail Committee).186 
The Colorado Retail Committee found moderate evidence that 
adolescents and young adults who are regular marijuana users are: (1) 
more likely than non-users to have cognitive and academic ability 
impairment for at least twenty-eight days after last use; (2) less likely 
than non-users to graduate from high school; (3) more likely than non-
users to increase their use and become addicted to marijuana in 
adulthood; and (4) more likely than non-users to use and become 
addicted to alcohol or tobacco in adulthood.187 The Colorado Retail 
Committee found “substantial evidence that adolescent and young 
adult marijuana users are more likely than non-users” to: (1) “use and 
be addicted to illicit drugs in adulthood;” and (2) develop psychotic 
symptoms or disorders like schizophrenia in adulthood.188 Quitting 
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marijuana was associated with lower risks of cognitive and mental 
health problems than for those who continued to use.189 
A prospective, longitudinal study was conducted to examine the 
association between persistent cannabis use and neuropsychological 
functioning in more than 1,000 individuals over a twenty-year period, 
starting at birth.190 Persistent cannabis use commencing in adolescence 
was associated with a statistically significant decline in overall 
neuropsychological functioning.191 Moreover, the cannabis users who 
began persistent use in adolescence and later discontinued cannabis use 
for at least one year did not see restored neuropsychological 
functioning.192 
Adverse effects from cannabis most frequently involve the CNS.193 
The most common effects are intoxication reactions, such as dizziness, 
drowsiness, and impairment of perceptual and sensory functions.194 
Twenty-four percent of patients using cannabis as an antiemetic became 
“high,” a state characterized by laughing, elation, and 
hyperawareness.195 Up to ten percent of medical marijuana users 
developed paranoia and abnormal thinking; more than ten percent 
developed amnesia and hallucinations; and less than one percent 
experienced depersonalization and confusion.196 
A meta-analysis of 83 studies was performed, investigating the 
relationship between cannabis and the age of onset of psychosis.197 The 
authors found the onset of psychosis among cannabis users occurred 
almost three years earlier than non-users, supporting their hypothesis 
that cannabis use has a causal role in the development of psychosis in 
predisposed individuals.198 
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THC use has been correlated with episodes of acute psychosis. In a 
randomized, controlled trial, intravenous doses of THC equivalent to 
typical cannabis cigarette usage (1.0 to 3.5% THC) produced acute 
cognitive and behavioral effects, including paranoid and grandiose 
delusions, hallucinations, depersonalization, distorted sensory 
perceptions, altered bodily perceptions, feelings of unreality, and 
extreme slowing of time.199 Subjects manifested a flat affect, reduced 
rapport, absence of spontaneity, psychomotor retardation, and 
emotional withdrawal.200 
Cannabis use increased the risk of adverse psychiatric effects for 
individuals with frank schizophrenia or with a family history of the 
disorder.201 Cannabis users developed schizophrenia an average of 1.5 
years earlier than non-users.202 In a study of 1,000 children followed 
from birth to age twenty-six, cannabis use was associated with a three-
fold risk of the development of psychotic disorders.203 The authors 
suggested that “psychologically vulnerable adolescents” should be 
strongly discouraged from using cannabis.204 
THC causes acute and transient episodes of anxiety, similar to 
panic attacks, in naïve cannabis users.205 In a study of French high-
school students, cannabis users reported significantly higher rates of 
depression and suicidal behaviors.206 Cannabis is one of the most 
frequently abused drugs in bipolar individuals, and there is a strong 
association between cannabis use and manic/hypomanic episodes or 
symptoms.207 Cannabis use also reduced the age of onset of bipolar 
disease by an average of nine years.208 
Frequent cannabis use may also lead to additional problems. Adults 
who smoked cannabis regularly as adolescents manifest impaired neural 
connectivity in the precuneus of the superior parietal lobe and the 
hippocampal fimbria,209 which control integration functions (alertness 
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and awareness) and learning and memory, respectively.210 Reduced 
connectivity has also been reported in executive functioning areas of 
the prefrontal cortex.211 Approximately nine percent of individuals who 
experiment with marijuana become addicted according to the DSM-IV 
criteria.212 The addiction rate increases to seventeen percent in teenage 
smokers and twenty-five to fifty percent in daily smokers.213 
The safety of cannabis use (12.5% THC) in chronic non-cancer pain 
was examined in a prospective cohort study.214 Non-serious adverse 
events occurred 818 times in the cannabis group compared with only 
581 events in non-users.215 Compared with controls, the rates of nervous 
system disorders, respiratory disorders, infectious disorders, and 
psychiatric disorders were significantly higher in the cannabis group.216 
In a similar study, the rate of non-serious adverse events was eighty-six 
percent higher in participants using medical cannabinoids versus 
controls.217 The incidence of serious adverse events was not higher in 
the cannabis group.218 
Foods and beverages infused with cannabis have added risks, 
including a greater risk of poisoning.219 Unlike smoked marijuana, 
edibles require two hours or more to reach their peak effect, subject to 
food intake and concomitant use of alcohol or other medications.220 This 
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delayed effect leads some individuals to use excess amounts, which can 
lead to symptoms of overdose and poisoning.221 
Drug interactions are common, especially when cannabis is used in 
conjunction with other CNS depressants, such as sedative-hypnotics or 
alcohol.222 THC is oxidized via the hepatic cytochrome P450 pathway; 
therefore, drugs that inhibit the P450 pathway may increase the 
bioavailability of THC and cause overdosing.223 Examples of these drugs 
include selective serotonin reuptake inhibitors (Prozac, Luvox), proton 
pump inhibitors (Prilosec, Tagamet), antibiotics (Biaxin, Emycin), 
anti-fungals (Nizoral, Diflucan), and calcium antagonists (Calan, 
Cardizem).224 
Health Canada has promulgated a list of nine precautions that their 
physicians should consider before recommending medical cannabis: 
 
 Cannabis should not be used in any person under the age of 18, 
or in any patient who has a history of hypersensitivity to any 
cannabinoid or to smoke. The adverse effects of cannabis use 
on mental health are greater during development, particularly 
during adolescence, than in adulthood . . . 
 
 Cannabis should not be used in patients with severe cardio-
pulmonary disease because of occasional hypotension, possible 
hypertension, syncope, or tachycardia . . . 
 
 Smoked cannabis is not recommended in patients with 
respiratory insufficiency such as asthma or chronic obstructive 
pulmonary disease . . . 
 
 Cannabis should not be used in patients with severe liver or 
renal disease. Patients with ongoing chronic hepatitis C should 
be strongly advised to abstain from daily cannabis use, as this 
has been shown to be a predictor of steatosis severity in these 
individuals . . . 
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 Cannabis should not be used in patients with a personal history 
of psychiatric disorders (especially schizophrenia), or a familial 
history of schizophrenia . . . 
 
 Cannabis should be used with caution in patients with a history 
of substance abuse, including alcohol abuse, because such 
individuals may be more prone to abuse cannabis, which itself, 
is a frequently abused substance . . . 
 
 Patients with mania or depression and using cannabis or a 
cannabinoid should be under careful psychiatric monitoring . . . 
 
 Cannabis should be used with caution in patients receiving 
concomitant therapy with sedative-hypnotics or other 
psychoactive drugs because of the potential for additive or 
synergistic CNS depressant or psychoactive effects. Cannabis 
may also exacerbate the CNS depressant effects of alcohol and 
increase the incidence of adverse effects. Patients should be 
advised of the negative effects of cannabis/cannabinoids on 
memory and to report any mental or behavioral changes that 
occur after using cannabis . . . 
 
 Cannabis is not recommended for women who are pregnant, 
breastfeeding, planning to become pregnant, or not using a 
reliable method of contraception.225 
 
Like most medications, cannabis has salutary effects and side 
effects.226 With the paucity of research performed in the United States, 
it is not possible to determine whether cannabis will ultimately be 
viewed as a blessing or a curse. Nonetheless, some individual or entity 
will be responsible for alerting patients to possible side effects. While 
the Learned Intermediary Doctrine puts the onus on doctors to warn 
patients about ethical pharmaceuticals, medical cannabis will be the 
exception. Medical cannabis is heavily marketed directly to patients by 
producers, and doctors only play a peripheral role as “recommenders” 
and not “prescribers.” Cannabis retailers are well advised to train their 
employees to discuss the use and misuse of cannabis as a way to limit 
liability. 
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V. Manufacturing Defects   
A. General Considerations 
When a product differs from the manufacturer’s design standards 
or intended result, or if it differs from supposedly identical products 
from the same manufacturer, the product has a manufacturing defect, 
to wit, the design has been executed in a defective manner.227 Moreover, 
the defective product must be “dangerous” and “unfit for its intended 
or foreseeable uses.”228 A claim of defective manufacture “involves a 
deviation from the product’s design specifications, to the injury or 
potential injury of a user.”229 Manufacturing claims can be brought in 
negligence, breach of warranty (implied and express), and strict 
liability.230 
A negligence claim has three elements: (1) a legal duty to use 
reasonable care; (2) a breach of that duty; and (3) the breach was the 
“proximate or legal cause” of the injury.231 Under the theory of strict 
liability in tort, a plaintiff has the burden of proving that: (1) he or she 
sustained an injury from the product; (2) the injury occurred because 
the product was defective; and (3) the defect existed when the product 
left the manufacturer’s control.232 
In a number of states, the Implied Warranty of Merchantability 
(U.C.C. § 2-314) has been codified in state law.233 In Arizona, A.R.S. 
§ 47-2314 is identical to U.C.C. § 2-314, which reads: 
B. Goods to be merchantable must be at least such as: 
1. Pass without objection in the trade under the contract 
description; and 
2. In the case of fungible goods, are of fair average quality within 
the description; and 
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3. Are fit for the ordinary purposes for which goods of that type 
are used; and 
4. Run, within the variations permitted by the agreement, of even 
kind, quality and quantity within each unit and among all units 
involved; and 
5. Are adequately contained, packaged, and labeled as the 
agreement may require; and 
6. Conform to any promises or affirmations of fact made on the 
container or label if any.234 
 The implied warranty of merchantability, which operates as a 
matter of law, “does not impose a general requirement that goods 
precisely fulfill the expectations of the buyer.”235 Under the U.C.C., the 
Implied Warranty of Fitness for Particular Purpose states: 
Where the seller at the time of contracting has reason to know 
any particular purpose for which the goods are required and that 
the buyer is relying on the seller’s skill or judgment to select or 
furnish suitable goods, there is unless excluded or modified under 
the next section an implied warranty that the goods shall be fit 
for such purpose.236 
This warranty is not limited to merchants and does not require any 
showing that the product was defective. 
U.C.C. § 2-313 sets out the elements of an express warranty: 
(1) Express warranties by the seller are created as follows: 
(a) Any affirmation of fact or promise made by the seller to the 
buyer which relates to the goods and becomes part of the basis of 
the bargain creates an express warranty that the goods shall 
conform to the affirmation or promise. 
(b) Any description of the goods which is made part of the basis 
of the bargain creates an express warranty that the goods shall 
conform to the description. 
(c) Any sample or model which is made part of the basis of the 
bargain creates an express warranty that the whole of the goods 
shall conform to the sample or model. 
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(2) It is not necessary to the creation of an express warranty that 
the seller use formal words such as “warrant” or “guarantee” or 
that he have a specific intention to make a warranty, but an 
affirmation merely of the value of the goods or a statement 
purporting to be merely the seller’s opinion or commendation of 
the goods does not create a warranty.237 
Under various codes, statutes, and the common law, medical 
marijuana product liability claims can be prosecuted for manufacturing 
defects when the edible product differs from its intended result and the 
product is more dangerous or unfit for its intended purpose under the 
theories of negligence, strict liability, and implied warranty. 
B. Medical Marijuana Manufacturing Defect Claims 
1. Pesticides 
The presence of a harmful pesticide in unprocessed cannabis is most 
likely a manufacturing defect, which may result in contamination of the 
final product with toxic chemicals or inaccurate concentrations of THC 
and other active components. When a product contains banned 
pesticides or unacceptable levels of permissible pesticides, it has 
deviated from the manufacturer’s specifications. Pesticides, by their 
very nature, have the potential to cause physical injury to humans.238 
If an injury occurs from an improper pesticide in cannabis, 
manufacturing defect claims may be made under the theories of 
negligence, strict liability in tort, and warranty. 
The Environment Protection Agency (EPA) sets strict standards 
for permissible levels of pesticides in commodities sold in the United 
States, typically in the range of 10 to 10,000 parts per billion.239 
Unfortunately, the EPA has refused to regulate pesticides in cannabis 
plants, citing marijuana as an illegal drug under federal law.240 
Consequently, pesticide regulation in marijuana cultivation can be 
controlled by the states.241 While the EPA has not established standards 
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http://cannabissafetyinstitute.org/wp-content/uploads/2015/06/CSI-
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for cannabis,242 it is reasonable to extrapolate that the permissible 
pesticide level would be comparable to other regulated commodities. 
Thus, states have used EPA regulations as guidelines for cannabis.243 
In Oregon, cannabis samples contained pesticide concentrations in 
excess of 10,000 parts per billion in twelve percent of the cases and in 
excess of 100,000 parts per million in 1.9% of the samples.244 Moreover, 
cannabis extracts frequently have THC concentrations five to ten times 
higher than cannabis flower.245 “THC might concentrate at five to seven 
times what’s in the original plant material, but pesticides might 
concentrate up to 100 times their original level.”246 As manufacturers 
work to get higher THC levels for the final product, pesticide levels are 
concentrating at a much higher rate. These pesticide levels grossly 
exceed acceptable tolerances for any commodity sold to the public for 
human consumption.247 
The study of cannabis from Oregon shows a widespread pesticide 
problem. For example, 389 samples of cannabis flower and 154 samples 
of cannabis extract (concentrate) were tested for sixty-five pesticides.248 
Of the samples tested, seven percent of flower and twenty-four percent 
of concentrate samples exceeded Oregon’s statutory pesticide 
tolerances.249 Some concentrates were found to contain the pesticides 
carbaryl, myclobutanil, and chlorfenapyr at levels greater than 100,000 
parts per billion, grossly exceeding acceptable levels for these pesticides 
in any commodity.250 Moreover, chlorfenapyr is not permitted in any 
food commodities.251 
In 2015, Oregon Live reported the results of its own testing in “A 
Tainted High.”252 They found that cannabis extract sold to medical 
marijuana patients had unacceptable levels of pesticide even though the 
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products passed mandated state testing.253 Of the ten concentrates 
tested by independent labs, eight tested positive for excessive pesticide 
levels.254 Of the fourteen pesticides found in those eight samples, six 
were classified by the federal government as possibly or probably 
carcinogenic.255 The Oregonian article suggested that laboratory 
certified products sold at dispensaries are likely to contain inconsistent 
and unacceptable levels of pesticide concentrations or banned 
pesticides.256 
The Oregonian determined that Mad Farmaceuticals’ OG Propane 
Hash Oil extract contained the active ingredient in Raid insecticide as 
well as three pesticides not approved for use in Oregon.257 Seven 
pesticides were found in Dab Society Dutch Treat extract, including 
bifenthrin, one of the pesticides on the EPA’s list of carcinogens.258 The 
concentration was so high (0.5 to 0.8 parts per million), that one 
toxicologist suggested that the plants used to make Dutch Treat must 
have been “soaked” in bifenthrin prior to harvesting.259 
A case involving the misuse of pesticides in marijuana cultivation 
was filed in Denver, Colorado on October 5, 2015.260 Brandan Flores 
and others filed suit against LivWell, Inc., a cannabis grower and 
operator of at least fourteen retail marijuana dispensaries in Colorado.261 
During the first quarter of 2015, LivWell employed a chemical 
“cocktail” including the fungicide, Eagle 20, to rid the cannabis plants 
of fungus, mites, worms, and other natural agents.262 Eagle 20 was not 
on the list of approved pesticides in Colorado at that time.263 When 
burned during the process of smoking marijuana, Eagle 20 releases 
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hydrogen cyanide gas, a potent and well-known poison, directly into 
the lungs of the smoker.264 
After being alerted to the use of Eagle 20, the Denver Department 
of Environmental Health placed a hold on 60,000 marijuana plants 
pending an assay of the residue.265 The hold was removed after the 
Department found acceptable levels of pesticide for vegetation, 
although the range would have been too high for tobacco.266 Individuals 
who unknowingly smoked Eagle 20-contaminated cannabis filed a class 
action lawsuit, alleging breach of contract, breach of implied covenant 
of good faith and fair dealing, breach of express warranty, breach of 
implied warranty for a particular purpose, breach of implied warrant of 
merchantability, intentional misrepresentation and concealment of 
material facts, unjust enrichment, and civil conspiracy.267 Plaintiffs did 
not assert bodily injury, only that they overpaid for a product with a 
manufacturing defect.268 
In response, Defendant LivWell filed a motion to dismiss, which 
was granted on February 11, 2016.269 The court held that the plaintiffs 
lacked standing because they did not suffer any physical, emotional, or 
economic injuries. 
Dismissal of the case against LivWell was anticipated for lack of 
damages. However, had the plaintiffs been able to show a cognizable 
injury-in-fact, the case would likely have been heard by a jury. As a 
consequence of this case, Eagle 20 was banned, and marijuana 
manufacturers and distributors recalled forty different contaminated 
cannabis products during 2016.270 
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2. Heavy Metals and Fungus 
At least one author has reported that medical marijuana is often 
laced with heavy metals and fungus, which are derived from the soil in 
which the marijuana grows.271 Concentrating the THC (which many 
manufacturers aim to do) can lead to increased amounts of heavy 
metals in the end product.272 Some manufacturers also employ butane, 
another toxic chemical, to strip the plant of many other compounds to 
maximize the percent of THC and profitability.273 
One such fatality related to medical marijuana contamination likely 
occurred in early 2017.274 According to CBS News, a young California 
man undergoing intensive cancer chemotherapy and stem cell therapy 
succumbed to a rare systemic fungal infection.275 He smoked medical 
cannabis for the relief of chemotherapy-induced nausea and vomiting.276 
After his death, twenty samples of medical marijuana taken from across 
the state were predominantly contaminated with the same rare fungus 
that caused his demise.277 Contaminated cannabis is the suspected cause 
of at least one other life-threatening fungal infection in a non-
immunocompromised cannabis smoker.278 
3. Inaccurate Medical Marijuana Testing 
Testing for THC concentration in cannabis, particularly edibles, is 
notoriously inaccurate.279 When products with a high THC 
concentration are incorrectly labeled with a lower THC concentration, 
this manufacturing defect may be responsible for the untoward effects 
of excess THC consumption. Multiple parties along the chain of product 
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distribution may be liable for the injury. Moreover, failure to properly 
test THC concentrations violates state law and is negligence per se.280 
In 2014, the Oregon Live opened another investigation by testing 
the THC concentration of fifteen cannabis-infused edibles and 
comparing it to the labeled concentration.281 Only one of fifteen samples 
was accurately labeled.282 Two products underestimated the THC 
concentration.283 For example, cannabis ice cream had fifty-four percent 
more TCH than the stated amount.284 Twelve products overstated the 
THC concentration.285 Chocolate chip cookies were found to have fifty-
two milligrams of THC instead of the indicated 197 milligrams.286 Como 
Treats pizza was labeled as having 350 milligrams of THC but 
contained only fifty-two milligrams – an eighty-five percent 
difference.287 The Oregonian also pointed out that product labels were 
“inconsistent and confusing” and “[o]nly four [edibles] had expiration 
dates.”288 
The accuracy of cannabis labeling was reported on in the Journal 
of the American Medical Association.289 Seventy-five marijuana edibles 
- baked goods, beverages, and candy - were purchased in random 
dispensaries located in San Francisco, Los Angeles, and Seattle.290 Two 
samples of each product were assayed for THC and CBD levels using 
state of the art, high-performance liquid chromatography.291 Accurate 
labeling was defined as within +/- 10% of labeled values, consistent 
with typical United States Pharmacopeia requirements that drugs meet 
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a 90-110% potency specification.292 Of the thirteen products labeled for 
CBD, none were accurately labeled; nine were over-labeled and four 
were under-labeled.293 With respect to THC content, only seventeen 
percent of the edibles were accurately labeled, sixty percent were over-
labeled, and twenty-three percent were under-labeled.294 Thus, eighty-
three percent of the samples were inaccurately labeled for THC 
concentration. Insufficient THC concentration is unlikely to produce 
the desired medical benefits. Excessive THC places patients at risk for 
adverse effects.295 
When medical marijuana is labeled with the incorrect THC 
concentration, there is a viable claim for breach of an express warranty. 
The THC concentration is a description of the goods and forms part of 
the basis of the bargain. If the producer or retailer was aware, or should 
have been aware, that the product was mislabeled and likely to cause 
harm, fraud may be added to the claim. If testing has not been 
performed or performed in an inadequate manner, the plaintiff may 
have a prima facie claim for negligent misrepresentation. 
Medical marijuana marked with the incorrect THC concentration 
is not considered of average quality, would not pass without objection 
in the trade, and is not fit for the ordinary purposes for which it is used. 
Therefore, mislabeled cannabis breaches the implied warranty of 
merchantability. 
Consumers of medical marijuana probably lack the ability to 
differentiate between dozens of strains with various chemical 
compositions. In the current paradigm for obtaining medical marijuana, 
the retailer often possesses the most knowledge about the products and 
their effects. This places the retailer in the best position to assist the 
consumer in selecting a cannabis strain or an edible that is suitable for 
treating a specific symptom or debilitating condition. This is especially 
true in certain diseases, like epilepsy. One study reported a reduction 
in seizures of fifty percent or more in 272 patients with the use of 
artisanal forms of cannabis very high in CBD.296 Strains low in CBD 
were significantly less efficacious.297  
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If the customer asks the seller to recommend a cannabis strain or 
an edible to treat seizures, the customer is relying on the seller’s skill 
and judgment to select the proper product. The seller must understand 
that only a product with a very high CBD concentration will be 
efficacious. If the seller recommends a product without the requisite 
concentration of CBD because the medical marijuana has been 
incorrectly assayed and labeled or because the seller is unaware of the 
association between CBD concentration and seizure abatement, the 
seller has breached the warranty of fitness for a particular purpose. 
Manufacturing defect claims will be prolific without significant 
reforms in the cannabis industry. Plants need to be cultivated without 
noxious pesticides, heavy metals, or fungi. Concentrations of THC and 
CBD need to be accurate assayed and labeled. Retailers should know 
which cannabis strain is an effective remedy for a particular symptom 
or disease. 
VI. Defective Design 
A. Theory 
At the most basic level, a defectively designed product is one 
designed in a way that is not suitable or safe for its intended purpose. 
Courts have articulated various criteria and tests for determining 
whether a design is defective. Nonetheless, it is generally true that the 
tests advanced under theories of strict liability in tort, negligence, and 
breach of implied warranty are comparable.298 
The Restatement (Second) of Torts § 402A refers to a product that 
is “in a defective condition unreasonably dangerous . . . .”299 The term, 
“unreasonably dangerous,” has been defined as more dangerous than an 
average consumer expects, so risky that a reasonable seller would not 
sell the product, or that the risks of the product’s design outweigh its 
benefits.300 
Courts have chosen consumer expectations,301 risk-utility analysis,302 
or both, to ground strict tort liability.303 In Arizona, for example, strict 
reliability requires three premises: (1) the product is “in a defective 
condition unreasonably dangerous;” (2) the product does not perform  
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as safely as expected by an ordinary consumer when used in a 
reasonable or intended fashion; and (3) the design’s risks outweigh its 
benefits.304 Comment g of the Restatement (Second) of Torts § 402A is 
incorporated as part of the premise: “[t]he rule stated in this Section 
applies only where the product is, at the time it leaves the seller’s hands, 
in a condition not contemplated by the ultimate consumer, which will 
be unreasonably dangerous to him.”305 On the other hand, a negligence 
claim starts with the contention that the product’s design does not meet 
its intended purpose306 and the manufacturer has not made the product 
safe for its intended uses by taking reasonable care in the product’s 
design.307 Regardless of whether the claim is filed under theories of strict 
tort liability or negligence, Arizona holds that when the user knows of 
the dangers, when the dangers are very obvious, or when the dangers 
are widely known, the manufacturer is not liable for those dangers.308 
Cases asserting a breach of the implied warranty of merchantability 
either: (1) use a generalized test for defective design, such as fitness for 
the product’s intended purpose; or (2) consider the product’s safety for 
its intended use as a measure of fitness.309 
The decision of how to characterize a pharma-pseudical, such as 
medical marijuana, involves a battle between the Second and Third 
Restatements of Torts and their respective comments. Regarding 
prescription drugs, the Second Restatement states that manufacturers 
should not be subject to strict tort liability for drugs that have 
therapeutic benefit but are also “unavoidably unsafe.”310 In the Third 
Restatement, a product is defective when a reasonable alternative 
design would have limited or eliminated the foreseeable risk inherent in 
the use of the product.311 The most radical approach is taken by the 
Third Restatement, which limits design defects to those drugs that no 
reasonable health care provider, knowing the foreseeable risks and 
benefits, would prescribe for any patient.312 In other words, if a drug is 
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prescribed by a reasonable healthcare provider for any reasonable 
indication, it is not defectively designed. 
Certain basic facts must be known to determine whether a medical 
cannabis edible is defective. Are cannabis edibles useful for any medical 
purpose? If so, what are the indications? What are the risks? Are edibles 
safe, unavoidably unsafe with a therapeutic benefit, or unreasonably 
dangerous? Would a reasonable alternative design diminish the 
foreseeable risk? 
B. Defective Design in Medical Marijuana 
Marijuana-infused edibles are likely to be the main source of 
products liability litigation in medical marijuana. For edibles to be safe, 
they must have a reasonable concentration of THC that is uniform from 
one batch of edibles to another. Proper product sampling techniques 
and accurate testing by high quality laboratories are required. The 
product must also have a portion size that is reasonable relative to the 
total dose of THC in the product. 
Stoney Bakes produces a double chocolate chip cookie. It resembles 
a true home-baked cookie, and has received five-star rave reviews on 
the Leafly website.313 The cookie is described as “fresh and moist,” “very 
tasty,” and “A+ top quality.”314 One user, plagued by untreatable, 
bimonthly migraine headaches, reports obtaining complete relief from a 
headache within two hours of eating the cookie.315 On its face, the cookie 
appears to be a very well-made and successful product; however, it has 
a very serious design defect that makes it unreasonably unsafe. 
The suggested THC dose in an edible for a new cannabis user is 
five milligrams.316 Experienced users often take at least a ten-milligram 
dose.317 As in most areas of medicine, the smallest effective dose of 
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medication is preferred because it lessens the number and severity of 
side effects.318 
A cookie this size is typically eaten all at once. Many people may 
even have more than one. The problem with Stoney Bakes’ product is 
that one cookie contains 250 milligrams of THC,319 enough THC for 
fifty novice users or twenty-five experienced users. To obtain a five-
milligram dose of THC, the cookie must be divided in fifty equal pieces, 
a virtual impossibility. Then, just one piece can be consumed, and I’ll 
“bet you can’t eat just one.”320 Because it is highly likely that a novice 
consumer of this THC-infused cookie will overdose on THC based on 
the minuscule serving size, the cookie is in a defective condition and 
unreasonably dangerous. A normal consumer would not anticipate the 
need to cut a cookie into fifty equal pieces and eat just one to obtain 
the correct dose; therefore, the cookie is not as safe as an ordinary 
consumer would expect it to be when used in a reasonable fashion. 
Finally, the design’s risks greatly outweigh its benefits. A safer 
alternative design is simple – put less THC in the cookie. For example, 
the cookie could be made with a single dose of THC, perhaps 2.5 
milligram, 5.0 milligram, or 10.0 milligram cookies, for consumption in 
one sitting. Instead of charging $20 for a 250 milligram cookie,321 the 
retailer could charge $5 for a 10.0 milligram cookie. Profit margins 
would skyrocket and liability would tumble. In other words, 
individually wrapped servings with proper dosages would eliminate the 
design defect and are eminently feasibly. 
Producers can alter Cannabis sativa plants in various ways and 
usually aim for high THC concentration hybrids.322 A consumer could 
ground a defective design claim on the fact that the design of marijuana 
plants or its derivatives created to additional health risks, made the 
product more dangerous in some way, or increased its addiction 
potential. 
The potency of cannabis has changed dramatically over the past 
two decades. The THC concentration of 38,681 samples of marijuana 
confiscated by the DEA between 1995-2014 was assayed in a 2016 
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study.323 Two trends were evident. First, the average potency of THC 
increased linearly from four percent in 1995 to twelve percent in 2014, 
a three-fold increase.324 Second, the concentration of CBD dropped from 
0.28% in 1995 to 0.15% in 2014.325 The increased THC potency is 
desirable for growers and retailers because consumers will pay more for 
higher concentrations of THC that engender greater euphoric effects for 
the same amount ingested (or smoked).326 
The effects of CBD have been reviewed at length.327 In many ways, 
CBD is the antithesis of THC. CBD inhibits the reuptake and 
degradation of anandamide, an endogenous cannabinoid, while THC 
results in relative depletion of anandamide. Anandamide depletion 
causes the psychotomimetic effects of THC.328 CBD exerts agonist 
activity at the 5-hydroxytryptamine receptors (serotonin receptors), 
mediating its anxiolytic, antidepressant, and precognitive effects.329 
While CBD has salutary effects in the clinical setting,330 THC use is 
associated with anxiety, mood disturbances, sleep disturbance, 
depression, mania, and schizophrenia. 331 
Medical marijuana that is designed to maximize THC and minimize 
CBD may be defectively designed for therapeutic purposes. It is not fit 
for its intended purpose because it may promote, rather than treat, a 
symptom or a disease. High THC concentration also makes marijuana 
more addictive,332 engendering more frequent and intensive use. An  
323. Mahmoud A. ElSohly et al., Changes in Cannabis Potency Over the Last 
2 Decades (1995-2014): Analysis of Current Date in the United States, 79 
BIOLOGICAL PSYCHIATRY 613, 614-616 (2016). 
324. Id. 
325. Id. 
326. Mike Pizzo, If You’re Buying Your Weed Solely on the THC Level, You’re 
Doing it Wrong, MEDIUM (May 5, 2017), https://medium.com/ 
trykecultivator/if-youre-buying-your-weed-solely-based-on-the-thc-level-
you-re-doing-it-wrong-ec5422d4ddfd. 
327. Rong et al., supra note 15. 
328. Id. at 214. 
329. Id. 
330. Id. at 215. 
331. Amber L. Bahorik et al., Patters of Marijuana Use Among Psychiatry 
Patients with Depression and its Impact on Recovery, 213 J. AFFECTIVE 
DISORDERS 168, 170 (2017); Keren I. Bolla et al., Sleep Disturbance in 
Heavy Marijuana Users, 31 SLEEP 901, 906 (2008); Nora D. Volkow et 
at., Decreased Dopamine Brain Reactivity in Marijuana Abusers is 
Associated with Negative Emotionality and Addiction Severity, 111 Proc. 
of the Nat’l Acad. Sciences of the U.S. E3149, E3155 (2014); Wayne Hall 
& Louisa Degenhardt, Cannabis Use and the Risk of Developing a 
Psychotic Disorder, 7 WORLD PSYCHIATRY 68, 70 (2008). 
332. Marijuana, NAT’L INST. DRUG ABUSE, https://www.drugabuse.gov/ 
publications/drugfacts/marijuana. 
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ordinary consumer would not reasonably anticipate that medical 
marijuana would make his or her symptom or disease worse and foster 
addiction. An alternative design (low THC/high CBD) is safer, 
imminently feasible, less costly, and likely to eliminate many of the 
foreseeable risks of high THC edibles. 
Defective design claims will arise in cannabis production. At 
present, numerous edibles are unreasonably dangerous because they 
contain concentrations of THC that will overdose the naïve or average 
user. In addition, production of edibles high in THC and low in CBD 
tends to increase the toxicity of cannabis while lowering its medicinal 
utility. 
VII. Failure to Warn 
A. General Considerations 
Products may be defective despite flawless design and precise 
manufacture. When a product becomes dangerous due to a lack of 
adequate instructions or warnings, the “failure to warn” makes the 
product defective.333 “[M]anufacturers have a duty to warn consumers 
about the hazards inherent in their products,”334 including their safe 
and proper use. The duty to warn extends to “latent dangers resulting 
from foreseeable uses” of the product that the manufacturer knew, or 
should have known, and to unintended uses of the product that were 
reasonably foreseeable.335 In general, there is no duty to warn of obvious 
dangers. 
The Restatement (Third) of Torts also characterizes warning 
defects: 
§ 2 Categories of Product Defect 
A product is defective when, at the time of sale or distribution, it 
contains a manufacturing defect, is defective in design, or is 
defective because of inadequate instructions or warnings. A 
product: 
. . . . 
(c) is defective because of inadequate instructions or warnings 
when the foreseeable risks of harm posed by the product could 
have been reduced or avoided by the provision of reasonable 
instructions or warnings by the seller or other distributor, or a 
predecessor in the commercial chain of distribution, and the 
 
333. Barker v. Lull Eng’g Co., 573 P.2d 443, 452 (Cal. 1978). 
334. Taylor v. Elliot Turbomachinery Co., 171 Cal. App. 4th 564, 577 (2009). 
335. Liriano v. Hobart Corp., 92 N.Y.2d 232, 237 (N.Y. 1998). 
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omission of the instructions or warnings renders the product not 
reasonably safe.336 
In Arizona, “product liability action” is defined as: 
any action brought against a manufacturer or seller of a product 
for damages for bodily injury, death or property damage caused 
by or resulting from . . . the failure to warn or protect against a 
danger or hazard in the use or misuse of the product or the failure 
to provide proper instructions for the use or consumption of any 
product.337 
A complaint alleging that a manufacturer failed to provide 
adequate warnings of a product’s dangers may be brought under at 
least three legal doctrines: strict liability, implied warranty, and 
negligence.338 The failure to warn may be viewed as negligent under a 
negligence theory, as the defect itself under strict liability in tort, or as 
a breach of the warranty of merchantability since the product is not fit 
for ordinary uses without the warning. 
B. Warnings About Pharmaceuticals 
Earlier, this article described how prescription drugs are different 
from other products.339 Prescription drugs are even described as 
“unavoidably unsafe products.”340 However, they are not considered 
defective or unreasonably dangerous when accompanied by proper 
directions for use and adequate warnings of potential side effects.341 A 
pharmaceutical manufacturer has a duty to warn of potential side 
effects of a medication that are known or knowable in view of the 
medical and scientific knowledge at the time of manufacture.342 Because 
pharmaceutical manufacturers receive constant feedback about drug 
 
336. RESTATEMENT (THIRD) OF TORTS § 2(c) (AM. LAW INST. 1977). 
337. Ariz. Rev. Stat. Ann. § 12-681(5) (2018). 
338. David G. Epstein, Products Liability: Defenses Based on Plaintiff’s 
Conduct, 1968 UTAH L. REV. 267, 268 (1968). 
339. See discussion supra note Part III.  
340. RESTATEMENT (SECOND) OF TORTS § 402A cmt. k (AM. LAW INST. 1965). 
341. Aaron v. Wyeth, No. 2:07cv927, 2010 WL 653984, at *5, *6 (W.D. Pa. 
Feb. 19, 2010); ELLEN FLANNERY & SANDFORD N. GREENBERG, WOMEN 
AND HEALTH RESEARCH: ETHICAL AND LEGAL ISSUES OF INCLUDING 
WOMEN IN CLINICAL STUDIES VOL. 2 93 (Anna C. Mastroianni et al. eds., 
1994). 
342. Muilenberg v. Upjohn Co., 320 N.W.2d 316, 331 (Mich. Ct. App. 1982). 
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side effects and dangers from multiple sources, they have a continuing 
duty to warn.343 
 In a negligence action, a drug manufacturer’s liability is based 
on its duty. In other words, these actions depend on whether a duty to 
warn existed, what the nature of the duty was, whether there was a 
breach of that duty, and whether the breach of the duty proximately 
caused the plaintiff’s injury.344 
A warning is sufficient when it is reasonable.345 A reasonable 
warning must: (1) describe the extent of the danger; (2) convey the 
seriousness of the danger; (3) alert a prudent health care practitioner 
to the danger; and (4) present the information in a satisfactory 
manner.346 Warnings about specific drugs should include: (1) harmful 
propensities of the drug known (or that should be known) to the 
manufacturer; (2) side effects; (3) dangerous interactions with other 
drugs; and (4) potential exacerbation of other medical conditions by 
the drug.347 A manufacturer must possess the knowledge of an expert in 
the relevant area of medicine and keep current with the scientific 
literature and discoveries in the field.348 The duty to warn extends to 
the risks the pharmaceutical manufacturer discovers from continuous 
monitoring of drug safety.349 
In strict liability actions under the Restatement (Second) of Torts, 
or under products liability in the Restatement (Third) of Torts, 
a drug manufacturer’s failure to adequately warn of side effects 
associated with a prescription drug renders the drug ”unreasonably 
dangerous,” or “not reasonably safe” and therefore defective.350 Strict 
tort liability is not concerned with notions of culpability.351 Unlike 
 
343. The duty to warn may vary by state requirements. RESTATEMENT (THIRD) 
OF TORTS: PRODUCTS LIABILITY §10(a-b) (AM. LAW INST. 1997); Kenneth 
Ross, Post-Sale Duty to Warn: A Critical Cause of Action, 27 WM. MITCHELL 
L. REV. 339, 346 (2000); Brian J. Hunt, Is the Door Opening for Plaintiffs?, FOR 
THE DEFENSE 60, 61 (2014). 
344. See Muilenberg v. Upjohn Co., 320 N.W.2d at 365. 
345. Id. 
346. Ehlis v. Shire Richwood, Inc., 233 F. Supp. 2d 1189, 1196 (D. N.D. 2002). 
347. Weilbrenner v. Teva Pharmaceuticals, 696 F. Supp. 2d 1329, 1333-40 
(M.D. Ga. 2010). 
348. Braun v. Roux Distrib. Co., 312 S.W.2d 758, 763 (Mo. 1958); Krug v. 
Sterling Drug, Inc., 416 S.W.2d 143, 149 (Mo. 1967). 
349. Brittany L. Raposa, Caveat Emptor: Protecting Inexpensive Generic 
Drugs at the Expense of Patient Safety, 27 HEALTH LAW. 28, 29 (2015). 
350. RESTATEMENT (SECOND) OF TORTS § 402A (AM. LAW INST. 1965); 
RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 6 (AM. LAW 
INST. 1997). 
351. Strict Liability, JUSTIA, https://www.justia.com/injury/negligence-
theory/strict-liability/ (last visited Dec. 18, 2018). 
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negligence, strict liability for failure to warn extends beyond the 
manufacturer to all entities in the supply chain.352 
In implied warranty actions, drug manufacturer liability may be 
similarly analyzed in terms of a duty to warn;353 however, it has also 
been suggested that the implied warranty of merchantability does not 
apply to prescription drugs because they are characterized as 
unavoidably unsafe ab initio.354 
In failure to warn cases involving unavoidably dangerous drugs, the 
standards for liability under negligence and strict liability are very 
similar or even “functional equivalents.”355 Regardless of the claim or 
claims asserted in a failure to warn case, the basic factual elements that 
must be proven are fundamentally the same.356 In Werner, the Fourth 
Circuit observed that any distinction between negligence and strict 
liability diminishes considerably in failure to warn cases.357 Whether the 
defendant exercised due care in formulating the warning is the issue 
under negligence,358 while under strict liability theory, the issue is 
whether an inadequate warning created an unreasonably dangerous 
product.359 The salient question is whether the warning was adequate. 
If the manufacturer provided an adequate warning, Restatement 
(Second) of Torts § 402A, comment k, makes it clear that 
a drug manufacturer is not strictly liable for injuries caused by an 
unavoidably dangerous prescription drug. 
A warning is only adequate when it is directed at the correct party. 
In Part III, the Learned Intermediary Doctrine and its three recognized 
exceptions were discussed (minor children, direct marketing, and 
patient-driven choice). One example of an exception is mass vaccination 
cases where vaccines were marketed directly to consumers. The Ninth 
Circuit has held that the manufacturer knew that each individual 
patient would not have been evaluated and counseled by a physician in 
advance of the immunization; therefore, the usual risks and benefits of 
 
352. Cf. 8 Am. Jur. Proof of Facts 3d 547 (last updated 2018); see generally 
Randy R. Koenders, Annotation, Products Liability: Liability of 
Manufacturer or Seller as Affected by Failure of Subsequent Party in 
Distribution Chain to Remedy or Warn Against Defect of Which He 
Knew, 45 A.L.R. Fed. 4th Art. 777 (1986). 
353. Reyes v. Wyeth Laboratories, 498 F.2d 1264, 1276 (5th Cir. 1974). 
354. Taylor v. Danek Medical, Inc., No. Civ.A. 95–7232, 1998 WL 962062 at 
*7, *13-14 (E.D. Pa. Dec. 29, 1998). 
355. Feldman v. Lederle Laboratories, 479 A.2d 374, 386 (N.J. 1984). 
356. Cf. 8 Am. Jur. Proof of Facts 3d 547 (last updated 2018). 
357. Werner v. Upjohn Co., Inc., 628 F.2d 848, 858 (4th Cir. 1980). 
358. Id. at 858. 
359. Id. at 857. 
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treatment would not have been considered or discussed.360 In that 
circumstance, it was the responsibility of the manufacturer to ensure 
that vaccination warnings reached the consumer either directly or 
through the purchaser of the vaccine (i.e., the vaccinator).361 The Court 
equated this to over-the-counter drugs where warnings can be given 
with proper labeling, posters, and advertisements.362 
In the second exception, a manufacturer is also required to directly 
warn a consumer about a drug’s dangerous risks when that drug is 
directly promoted and marketed to consumers through advertising. In 
Perez v. Wyeth Labs, Inc., the Supreme Court of New Jersey held that 
the Learned Intermediary Doctrine was inapplicable when 
pharmaceuticals were directly marketed to consumers, and 
manufacturers were responsible to directly warn patients of a drug’s 
dangerous propensities. 363 If warnings were inadequate, manufacturers 
were subject to consumer claims for failure to warn.364 
Another exception concerned the long-term use of birth control 
pills. When a woman selects a contraceptive, the physician often plays 
a peripheral or secondary role in the selection.365 The choice is typically 
based on patient preference rather than the physician’s comprehensive 
discussion of the risks, benefits, and alternatives of any therapeutic 
modality.366 In that regard, the McDonald court held that a birth 
control pill manufacturer had a duty to directly warn consumers of the 
risks of its product, also noting that direct warnings were eminently 
feasible.367 
C. Failure to Warn and Adequately Label Marijuana Products 
Professor David Owen developed a helpful rubric for evaluating the 
adequacy of warnings based on content and form.368 Owen refers to 
content as, “Substantive Adequacy,” and relates it to the clarity and 
completeness of the description of a product’s specific risks.369 The form 
 
360. Davis v. Wyeth Laboratories, Inc., 399 F.2d 121 (9th Cir. 1968). 
361. See id. at 131. 
362. Id. 
363. Perez v. Wyeth Laboratories Inc., 734 A.2d 1245 (N.J. Sup. Ct. 1999). 
364. Id. at 1252. 
365. See Christine Dehlendorf et al., Women’s Preferences for Contraceptive 
Counseling and Decision Making, HHS PUBLIC ACCESS (Nov. 21, 2012), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026257/. 
366. Id. 
367. MacDonald v. Ortho Pharm. Corp., 475 N.E.2d 65, 70 (Mass. 1985). 
368. DAVID G. OWEN, PRODUCTS LIABILITY IN A NUTSHELL 284-95 (West 
Academic Publishing, 9th ed., 2015). 
369. Id. at 285-286. 
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of the warning is its “Procedural Adequacy,” describing the mode of 
conveyance of the message.370 
While the primary focus of this paper is on medical marijuana, it is 
at least as important that users of recreational marijuana be provided 
with appropriate and effective warnings and product labeling. 
Consumers generally understand that there are potential risks and side 
effects associated with the use of medications. Consumers may not 
appreciate the risks of using recreational marijuana, especially when the 
edible form of the product resembles common products and sizes that 
have been in the public domain for decades. Furthermore, in most 
states, medical marijuana users do not receive more product 
information than a purchaser for recreational purposes would.371 
The scope of the duty to warn with respect to medical marijuana 
has not been defined or articulated because the industry is still in its 
infancy, and clinical trials in the United States are very limited.372 
Nonetheless, failure to warn will likely be the most significant area of 
cannabis products liability litigation. All participants in the cannabis 
supply chain should consider what extent of disclosure is necessary to 
limit failure to warn liability. 
1. Kirk v. Nutritional Elements 
One medical marijuana case, Kirk v. Nutritional Elements, is being 
litigated predominantly on a theory of failure to warn.373 It is a sad case, 
but its themes are instructive. Kristine and Richard Kirk, a married 
couple in Denver, had three sons, ages seven, eleven, and thirteen.374 In 
early 2014, Richard purchased a THC-infused edible, Karma Kandy 
 
370. Id. at 286. 
371. John M. Malouff et al., Cannabis Users’ Recommended Warnings for 
Packages of Legally Sold Cannabis: An Australia-Centered Study, 1 
CANNABIS & CANNABINOID RESEARCH 239, 240 (2016). See 4 Differences 
When Serving Medical Marijuana Patients vs. Recreational Customers, 
INDICAONLINE (May 25, 2018), https://indicaonline.com/blog/4-
differences-serving-medical-marijuana-patients-vs-recreational-
customers/. 
372. Israel is the international leader in cannabis research with 110 active 
clinical trials. See Yardena Schwartz, The Holy Land of Medical 
Marijuana, U.S. NEWS (Apr. 11, 2017, 11:04 AM), https://www. 
usnews.com/news/best-countries/articles/2017-04-11/israel-is-a-global-
leader-in-marijuana-research. 
373. Kirk v. Nutritional Elements, Inc., No. 2016CV31310 (2d Dist. Colo. filed 
May 9, 2016). 
374. See Plaintiff’s First Amended Complaint and Jury Demand at 3, Kirk v. 
Nutritional Elements, Inc., No. 16CV31310 (2d Colo. May 9, 2016). 
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Orange Ginger, from Nutritional Elements.375 The product was 
packaged, sold, and distributed by Gaia’s Garden.376 It has been 
debated whether Richard purchased the edible to treat his back pain or 
whether it was for recreational use.377 
The product is described as a “delectable taffy”378 containing a “101 
milligram hybrid THC with Tears of Phoenix hash oil infused for a very 
high CBD concentrate.”379 The packaging did not contain any 
instructions about proper consumption or use.380 Specifically, there was 
no information about how much to take, whether it should be taken 
with food or drink, or how long the product required to take effect. 
There were no warnings about the possibility of an overdose or how to 
manage an overdose if it were to occur.381 No other printed literature 
was included with the purchase.382 Plaintiff’s counsel pointed out that 
there were more warnings and instructions on toothpaste, chewing gum, 
hand cream, and dog treats.383 
 
 
375. Emma Gannon, Insurer Refuses to Cover Marijuana Candy Murder, 
COURTHOUSE NEWS SERV. (May 8, 2017), https://www.courthousenews 
.com/insurer-refuses-cover-marijuana-candy-murder/; Bobbi Sheldon, 
Allison Sylte & Anastasiya Bolton, Man, High on Pot Candy, Get 30 
Years Prison for Killing Wife, USA TODAY, https://www.usatoday. 
com/story/news/nation-now/2017/04/07/husband-killed-wife-pot-candy 
/100190066/ (last updated Apr. 7, 2017). 
376. Gannon, supra note 375. 
377. Richard Kirk had been prescribed opiates for his back pain, but his blood 
test for opiates was negative immediately after the homicide. Denver Man 
Who Said Marijuana Made Him Kill His Wife Gets 30 Years, NBC NEWS 
(Apr. 7, 2017, 8:04 PM), https://www.nbcnews.com/news/us-
news/denver-man-who-said-marijuana-made-him-kill-his-wife-n744056. 
378. Karma Kandy, GAIA GARDEN,  http://gaias.atwebpages.com/product 
/karma-kandy/ (last visited Jan. 5, 2019). 
379. Gaia’s Garden Karma Kandy, MMJ MENU, https://mmjmenu.com 
/dispensaries/1313/menus/1313/menu_items/414021 (last visited Oct. 
19, 2018). 
380. David Kelly, He Got High and Killed His Wife. A Lawsuit Claims Edible 
Marijuana is to Blame, L.A. TIMES (June 1, 2016, 3:00 AM), 
http://www.latimes.com/nation/la-na-cannabis-homicide-20160531-
snap-story.html. 
381. Gaia’s Garden Karma Kandy – Orange Ginger – 101mg, MMJ MENU, 
https://mmjmenu.com/dispensaries/1313/menus/1313/menu_items/414
021 (last visited Oct. 20, 2018). 
382. Plaintiff’s First Amended Complaint and Jury Demand, Kirk v. 
Nutritional Elements, Inc., No. 16CV31310 (2d Colo. May 9, 2016). 
383. Id. 
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Figure 3. Kandy Karma Orange Ginger384 
 
By its appearance, the Karma Kandy Orange Ginger taffy 
resembles a caramel-colored Tootsie Roll. Richard Kirk bought a 
Karma Kandy like the one shown above, weighing 10 grams.385 For 
reference, the Tootsie Roll “Midgee” shown below weighs 6.7 grams.386 
A single serving of Tootsie Rolls is six Midgees weighing 40 grams.387 
 
Figure 4. Tootsie Roll Midgee388 
 
The Karma Kandy contains 101 milligrams of THC.389 According 
to Leafly, the world’s largest cannabis information resource, the 
“standard dose” according to Colorado’s edibles dosing guidelines is ten 
milligrams, “but a cannabis newbie or low-tolerance consumer should 
 
384. MMJ MENU, supra note 381. 
385. Plaintiffs’ First Amended Complaint and Jury Demand at 7, Kirk v. 
Nutritional Elements, Inc., No. 16-CV-31310 (2d Colo. May 9, 2016). 
386. Tootsie Roll, SELF NUTRITION DATA, http://nutritiondata.self.com 
/facts/sweets/8014/2 (last visited Oct. 2, 2018). 
387. Id. 
388. PIXABAY, https://pixabay.com/en/chocolate-candy-sugar-sweet-
2202140/ (last visited Dec. 14, 2018). 
389. Louise Boyle & Ashley Collman, Did this Legal Marijuana-Laced Candy 
Called ‘Karma’ Make a Husband Hallucinate and Shoot His Wife?, DAILY 
MAIL, https://www.dailymail.co.uk/news/article-2607372/Did-legal-
marijuana-laced-candy-make-man-hallucinate-shoot-wife.html (last 
updated Apr. 18, 2014). 
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start with half of that.”390 In other words, a regular cannabis user would 
eat one-tenth of one piece of Karma Kandy, and a cannabis-naïve user 
should start with one-twentieth of one piece of Karma Kandy. For 
comparison purposes, one-twentieth of a Karma Kandy is equivalent to 
one-fourteenth of a Tootsie Roll Midgee. It is difficult to imagine 
cutting a Tootsie Roll Midgee into fourteen equal pieces, each weighing 
0.5 gm, and eating just one. Richard Kirk was cannabis-naïve and 
should have eaten one-twentieth of the piece of Karma Kandy taffy. 
Instead, he consumed the entire piece, 101 milligrams of THC, at one 
time.391 
Richard reportedly became delirious, paranoid, and psychotic after 
consuming the Karma Kandy.392 Kristine called 911 at 9:30 p.m., 
relating to the operator that Richard was delusional and actively 
hallucinating, and the children were terrified.393 He rambled about the 
end of the world and asked Kristine and the children to kill him.394 
While Kristine spoke to the 911 operator, Richard shot her in the head 
with his revolver, killing her instantly.395 Fortunately, the children 
escaped.396 Police officers arrived on the scene and took Richard into 
custody.397 
A professor of medicine at Johns Hopkins opined that Richard 
suffered an acute psychotic reaction from a cannabis overdose.398 A 
forensic psychiatrist concluded that acute intoxication induced 
Richard’s cognitive distortions, especially in view of the fact that his 
personality profile was non-violent and non-aggressive.399 
A failure to warn suit was filed against the manufacturer and the 
dispensary under theories of strict liability in tort and negligence.400 
Claims were also filed under strict liability for misrepresentation against 
the entities and negligence against Richard.401 In February 2017, 
 
390. See generally 5 Tips, LEAFLY, supra note 316. 
391. Plaintiffs’ First Amended Complaint and Jury Demand at 7, Kirk v. 
Nutritional Elements, Inc., No. 16-CV-31310 (2d Colo. May 9, 2016). 
392. Id. at 5. 
393. Id. 
394. Id. 
395. Id. at 6-7. 
396. Id. at 5. 
397. Id. at 7. 
398. Id. at 19. 
399. Id. at 18-19. 
400. Id. at 20-21. 
401. Id. at 22-23. 
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Richard pled guilty to second-degree murder and was sentenced to 
thirty years in prison.402 The civil case is pending.403 
2. One Candy Bar: Sixteen Servings 
Maureen Dowd, a well-known columnist for The New York Times, 
reported her own frightening experience with THC-infused edibles in 
2014.404 Dowd purchased a THC-infused chocolate caramel bar similar 
to one of her childhood favorites. She took a few tiny bites, felt nothing, 
and took a few more.405 Just over an hour later, Dowd developed a 
hallucinatory and paranoid state of mind.406 Initially, Dowd thought she 
had died, but no one would tell her.407 It was not until the next morning 
that the effects began to subside.408 In preparation for the article, she 
interviewed a medical consultant at the dispensary. One chocolate 
caramel bar represented sixteen servings for novice users.409 The bar 
was not labeled with dosage information, and no one at the dispensary 
warned her about the delay in effect of the edible or the possibility of 
overdosing.410 
D. Suggestions for Reasonable Packaging and Verbal Warnings 
Kirk and Dowd are examples of the critical nature of dosage 
warnings, even for recreational users. Moreover, there are no additional 
protections or legal requirements for dosage warnings on products 
marketed to medical marijuana patients. Patients should start with low 
THC dosages and gradually increase until the desired effect is achieved 
without significant side effects. Certifying physicians could discuss 
dosages, but there is a paucity of medical literature or continuing 
medical education on cannabis therapeutics. Dispensary consultants 
should be required to discuss dosages. Most dispensary workers have 
 
402. Noelle Phillips, Richard Kirk Sentenced to 30 Years in Prison in 2014 
Observatory Park Slaying of his Wife, DENVER POST (Apr. 8, 2017, 12:12 
PM), https://www.denverpost.com/2017/04/07/richard-kirk-2014-
observatory-park-wife- homicide-sentencing/. 
403. Id. 
404. Maureen Dowd, Don’t Harsh Our Mellow, Dude, N.Y. TIMES (June 3, 
2014), https://www.nytimes.com/2014/06/04/opinion/dowd-dont-harsh-
our-mellow-dude.html. 
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personal experience with cannabis,411 which could be helpful to 
customers with questions or concerns. Beginning users should be told 
to start with 2.5 milligrams and not exceed 5.0 milligrams of THC; 
more experienced users may be advised that it is safe to increase dosage 
to 10.0 milligrams. Patients should be advised not to take cannabis 
edibles on an empty stomach because absorption is too rapid. Users 
should be cautioned about the time delay in experiencing the effect of 
the edible (up to two hours) and should be discouraged from consuming 
additional edibles before that time to prevent overdosing. 
Verbal instructions alone about cannabis use are insufficient. At a 
minimum, dosage instructions and warnings should appear on the 
product label in a reasonable size font. In addition, it would be prudent 
to give the patient the equivalent of a pharmaceutical package insert, 
albeit one with less technical language. Medical dispensary consultants 
ought to be trained to discuss the package insert and document the 
date and time of the discussion, just like when getting a prescription 
from a pharmacy. The discussion requirement need not be fully 
informed consent, but there should be a requirement for the most 
important information to be conferred with initial dispensation. 
Issues of short-term and long-term known health risks must be 
addressed, especially to vulnerable populations. However, the lack of 
clarity of the risks in the extant medical literature complicates matters. 
The most significant warnings should be given, but by whom? In the 
current structure, physicians claim to lack the time and the dispensary 
employees lack the knowledge. But, if no one takes the time to warn, 
everyone will get sued. 
Even without the desired level of clarity, there are certain warnings 
that should be de rigueur. The following groups should always be 
advised about the potential complications and side effects: 
 
 Pregnant women should be warned that cannabis use during 
pregnancy predisposes their offspring to be small in stature and 
at risk for cognitive dysfunction, inattention, and behavioral 
problems. Lactating women must be cautioned that cannabis 
metabolites are present in breast milk and their impact on a 
newborn is unknown. 
 
 Young adults and adolescents should be knowledgeable about 
the ongoing cognitive impairments and diminished academic 
success associated with cannabis use accompanied by the 
increased likelihood of addiction to marijuana, alcohol, and 
illicit drugs. 
 
 
411. Nancy Haug et al., Training and Practices of Cannabis Dispensary Staff, 
1.1 CANNABIS & CANNABINOID RES. 244, 247 (2016). 
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 Persons with mental health issues, such as depression, anxiety, 
and bipolar disorder, should be strongly warned about potential 
worsening of their condition. 
 
 Novice users must be educated about what being “high” is like, 
with its attendant euphoria, altered perception, cognitive 
impairment, and psychomotor retardation. Unlike recreational 
users, the “high” experienced by a medical marijuana user is 
often an undesirable side effect. The purpose of medical 
marijuana is to increase functionality and comfort without 
cognitive and perceptual impairment. 
 
Furthermore, the following should be discussed with every medical 
marijuana user: 
 
 There are risks to others, particularly the increased likelihood 
of accidents and injury while driving or operating heavy 
machinery. 
 
 What the symptoms of an overdose look or feel like. Users 
should be informed that if they develop paranoia, delusions, 
and hallucinations, they should seek emergency care and 
observation. The phone number to the local poison control 
center should be readily available with the dispensed product. 
 
 The clear contraindications to cannabis use. For example, 
individuals with schizophrenia or with uncontrolled mental 
illness should avoid cannabis unless it is used under the care of 
a knowledgeable psychiatrist; angina can be exacerbated by 
THC; patients allergic to Cannabis sativa or plants within the 
same genus should be strongly cautioned. 
 
There are numerous drug interactions that could produce serious 
side effects. The following is a list of the most important drugs and the 
type of interaction: 
 
 Chlorpromazine – requires increased dosage 
 
 Clozapine – clozapine level may rise rapidly after THC 
cessation 
 
 CNS Depressants – increased drowsiness and CNS depression 
when THC is combined with alcohol, opioids, sedative 
hypnotics, barbiturates, benzodiazepines, buspirone, 
antihistamines, muscle relaxants, and others 
 
 Disulfiram – possible mania or psychosis 
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 Hydrocortisone – increased serum cortisol 
 
 Indinavir – decreases peak concentration of this drug 
 
 Ketoconazole – increases peak THC concentration 
 
 MAO Inhibitors – orthostatic hypotension 
 
 Phenytoin – phenytoin level may rise rapidly after THC 
cessation 
 
 Warfarin – THC may enhance anticoagulant effect412 
E. Labeling and Packaging 
Proper labeling and packaging can increase safety of use and 
mitigate liability. A number of states have promulgated very specific 
rules for labeling and packaging of cannabis.413 Products sold in 
California are required to have the following comprehensive label on 
the product or insert, all in capital letters: 
  
 
412. COLO. DEP’T PUB. HEALTH & ENV’T, supra note 161, at 40. 
413. A State-by-State Guide to Cannabis Packaging and Labeling Laws, 
LEAFLY (Sept. 22, 2015), https://www.leafly.com/news/industry/a-state- 
by-state-guide-to-cannabis-packaging-and- labeling-laws [hereinafter State 
Labeling Laws, LEAFLY]. 
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GOVERNMENT WARNING: THIS PRODUCT CONTAINS 
CANNABIS, A SCHEDULE I CONTROLLED SUBSTANCE. 
KEEP OUT OF REACH OF CHILDREN AND ANIMALS. 
CANNABIS PRODUCTS MAY ONLY BE POSSESSED OR 
CONSUMED BY PERSONS 21 YEARS OF AGE OR OLDER 
UNLESS THE PERSON IS A QUALIFIED PATIENT. THE 
INTOXICATING EFFECTS OF CANNABIS PRODUCTS 
MAY BE DELAYED UP TO TWO HOURS. CANNABIS 
USE WHILE PREGNANT OR BREASTFEEDING MAY BE 
HARMFUL. CONSUMPTION OF CANNABIS PRODUCTS 
IMPAIRS YOUR ABILITY TO DRIVE AND OPERATE 
MACHINERY. PLEASE USE EXTREME CAUTION. 414 
Nevada has adopted a comprehensive system of labeling 
requirements for edibles: 
Labeling requirements for concentrated cannabis, edible 
marijuana products or marijuana-infused products for sale to 
medical marijuana dispensary. 
1.  A facility for the production of edible marijuana products or 
marijuana-infused products shall label all concentrated cannabis, 
edible marijuana products and marijuana-infused products before 
it sells the products to a medical marijuana dispensary and shall 
securely affix to the package a label that includes, without 
limitation, in legible English: 
(a) The name of the medical marijuana establishment and its 
medical marijuana establishment registration certificate number; 
(b) The production run number; 
(c) The date of production; 
(d) The date of final testing; 
(e) The date on which the product was packaged; 
(f) The cannabinoid profile and potency levels and terpenoid 
profile as determined by the independent testing laboratory, 
which may include the potential total THC but shall not include 
any other calculated level of THC; 
(g) If the product is perishable, the expiration date; 
(h) The total amount of THC measured in milligrams; 
 
414. Cal. Bus. & Prof. Code § 2612(c)(1)(B) (2016). 
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(i) A list of all ingredients and all major food allergens as 
identified in 21 U.S.C. § 343; 
(j) The net weight of the product; and 
(k) If concentrated cannabis was added to the product or if the 
product consists solely of concentrated cannabis, a disclosure of 
the type of extraction process used and any solvent, gas or other 
chemical used in the extraction process or any other compound 
added to the concentrated cannabis.415 
In addition to these labeling requirements, retail products are 
required to have additional information and at least six warnings 
related to “intoxicating effects,” potential health risks, and appropriate 
use of the product.416 There are even guidelines related to the placement, 
font, and size of the labels.417 
In an effort to prevent overdose and unintended exposure of 
children to cannabis, some states require that marijuana edibles be 
packaged in single use, single dose, child resistant packages, limited to 
between 5.0 and 15.0 milligrams of THC.418 California and Colorado 
limit edible dosages to 10.0 milligrams of THC.419 Most states have child 
resistant packaging requirements. Oregon’s packaging goes one step 
further by specifying packaging that is not attractive to minors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
415. Nev. Rev. Stat. § 453A.509 (2017). 
416. Nev. Rev. Stat. § 453A.512 (2017). 
417. Nev. Rev. Stat. §§ 453A.509, 512 (2017). 
418. State Labeling Laws, LEAFLY, supra note 413. 
419. Chris Roberts, California’s New Edibles Limits Will Ban Popular 
Products, LEAFLY (Nov. 27, 2017), https://www.leafly.com/news/ 
industry/californias-new-edibles-limits-will-ban-popular-products. 
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Figure 5. Oregon’s Packaging Requirements420 
 
In addition to text, warning symbols have been selected to identify 
products as containing marijuana: 
 
 
 
 
 
 
 
      
     
Colorado421                      Oregon422                    Washington423 
 
Figure 6. Warning Symbols from Different States and Cities 
 
 
420. OR. LIQUOR CONTROL COMM’N, MEDICAL & RECREATIONAL MARIJUANA 
PACKAGING AND LABELING GUIDE 3 (Aug. 2016), http://www.oregon.gov/ 
olcc/marijuana/Documents/Packaging_Labeling/PackagingandLabeling
Guide_V2.pdf. 
421. Responsible Use, COLO. MARIJUANA, https://www.colorado.gov/pacific/ 
marijuana/responsible-use (last visited Oct. 10, 2018). 
422. Marijuana and Your Health, OR. HEALTH AUTH., https://www.oregon.gov 
/oha/PH/PreventionWellness/marijuana/Pages/symbol.aspx (last 
visited Oct. 10, 2018). 
423. Cannabis Packaging and Labeling Resources, Wash St. Liquor & Cannabis 
Board, https://lcb.wa.gov/laws/labeling-resources (last visited Oct. 10, 
2018). 
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To effectively maximize safety and minimize liability, a balance 
needs to be struck between too little and too much information. Too 
little information leads to poorly informed patients and enhances 
liability for marijuana suppliers. If patients are given too much 
information, they will probably not read it. The cannabis purveyor will 
be less exposed to liability when detailed risks and instructions are 
dispensed with the product. My recommendations include the following: 
(1) single dose, child resistant packaging; (2) warning labels with 
symbols on the product; and (3) a warning and instruction sheet similar 
to a pharmaceutical package insert, but written in layperson’s language. 
VIII. Youth Marketing of Marijuana 
Medical marijuana can be recommended for individuals eighteen 
and over, although rare exceptions exist for younger patients.424 
Recreational users must be twenty-one.425 Marketing of marijuana in 
states that permit recreational use is supposed to be directed to 
individuals twenty-one years and older.426 However, in states with 
recreational use, medicinal use, or both, marketing is often directed to 
the younger Millennials, individuals currently between the ages of 
eighteen and twenty-five years.427 The marketing plan appears to be 
based on the fact that virtually anyone with a little knowledge and 
coaching can qualify for a medical marijuana card.428 It is only necessary 
to remember the new four-letter word, “pain.” 
The most popular criterion for medical marijuana qualification is 
chronic pain.429 Pain is entirely subjective and is hard to prove or 
disprove.430 In Arizona, a sizeable and disproportionate number of 
Millennials are afflicted with “chronic pain” despite that fact that they 
may have no history of a disease process that causes chronic pain and 
 
424. Medical Marijuana Age Requirement, MARIJUANA DRS., 
https://www.marijuanadoctors.com/blog/medical-marijuana-age- 
requirement/ (last visited Oct. 10, 2018). 
425. Id. 
426. Anna Gorman, In the Age of Legalization, Talking to Kids About 
Marijuana Gets Tougher, NPR (Nov. 10, 2009), https://www.npr.org/ 
sections/health-shots/2017/11/10/563051543/in-the-age-of-legalization-
talking-to-kids-about-marijuana-gets- tougher. 
427. Melissa Jenco, Study: Medical Marijuana Advertising Linked to Teen Use, 
AAP NEWS (May 18, 2018), http://www.aappublications.org/ 
news/2018/05/18/marijuanaads051818. 
428. See Josh Harkinson, How to Get a Pot Card (Without Really Trying), 
MOTHER JONES (Oct. 11, 2010), https://www.motherjones.com/ 
politics/2010/10/california-medical-marijuana-pot-card/. 
429. Hill et al., Cannabis and Pain: A Clinical Review 2.1 CANNABIS & 
CANNABINOID RES. 96, 97 (2017). 
430. Id. 
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have not had a medical evaluation or appropriate testing to determine 
the source of the pain.431 
In several states, the presence of chronic pain alone is not sufficient; 
the pain must be “debilitating.”432 It appears that some medical 
marijuana clinics set a very low bar for certification of “debilitated” 
individuals. For example, the complaint of back pain lasting more than 
six months is considered to be debilitating by some clinics, 
notwithstanding the fact that the patient is entirely functional and 
without physical limitations.433 The clinics use the catch phrase, “Get 
Legal,”434 which appears to roughly translate into: (1) come to the clinic; 
(2) get certified; and (3) use marijuana legally. 
Medical marijuana clinics frequently advertise in free newspapers 
available on college campuses.435 Their appeal to youth is undeniable. 
Advertisements contain eye-catching color and layouts.436 The names of 
the clinics evoke images of natural or organic products used in a holistic, 
patient-focused, and compassionate fashion letter.437 Some clinics 
advertise that customers do not need prior medical records; everything 
necessary can be done at the visit.438 However, in Arizona, it is almost 
certainly true that an individual with “a debilitating medical 
 
431. See, e.g., ARIZ. DEPT’ HEALTH SERV., ARIZONA MEDICAL MARIJUANA 
PROGRAM DECEMBER 2018 MONTHLY REPORT (2018), 
https://www.azdhs.gov/documents/licensing/medical-marijuana/reports 
/2018/2018-dec-monthly-report.pdf; Eli McVey, Chart: Arizona’s Massive 
Medical Marijuana Market Keeps Growing, MARIJUANA BUS. DAILY (Feb. 
5, 2018), https://mjbizdaily.com/chart-arizonas-massive-medical-
marijuana-market-keeps-growing/; Britt Hermes, I was a Pot Doctor; 
Naturopaths Blowing Smoke with Medical Marijuana, NATUROPATHIC 
DIARIES (Dec. 21, 2016), https://www.naturopathicdiaries.com/pot-
doctor-naturopaths-medical-marijuana/. 
432. How to Get a Legal Medical Marijuana Card or Authorization, LEAFLY, 
https://www.leafly.com/news/health/qualifying- conditions-for-medical-
marijuana-by-state (last updated Oct. 6, 2018). 
433. Chronic Pain Qualifies for Medical Marijuana In Ohio, OHIO MARIJUANA 
CARD, https://www.ohiomarijuanacard.com/pain (last visited Jan. 4, 
2019). 
434. GET LEGAL, http://getlegalarizona.com/ (last visited Oct. 21, 2018). 
435. See, e.g. The Holistic Center, METRO, (Oct. 21, 2018),  
http://boston.metro.us/html5/reader/production/default.aspx?pubname
=&edid=7e725dc3-7488-4753-8501-. 
436. See David K. Israel, 9 Medical Marijuana Ads, MENTAL FLOSS (Mar. 15, 
2010), https://mentalfloss.com/article/24200/9-medical- marijuana-ads. 
437. The 100 Best Dispensaries, CANNABIS NOW (Mar. 24, 2017), 
https://cannabisnow.com/100-best-dispensaries/. 
438. Jonathan Martin, No Medical Records? No Problem. Got My Pot Card 
at Hempfest, SEATTLE TIMES (Aug. 20, 2011, 6:28 PM), 
https://www.seattletimes.com/seattle-news/no-medical-records-no-
problem-got-my-pot-card-at-hempfest/. 
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condition,” as defined by A.R.S. § 36-2801(3), would not suffer from a 
lack of medical records.439 
Colorado has codified the limitations in retail marijuana youth 
marketing by adopting the standards of the alcohol industry.440 Retail 
marijuana establishments must refrain from television, radio, print, 
internet, and pop-up advertising unless the establishment has reliable 
evidence that no more than thirty percent of the audience for the 
television program, radio broadcast, print publication, or website is 
reasonably expected to be under the age of twenty-one.441 
RAND researchers442 collected data from 8,200 students enrolled in 
grades six through eight (mean age of thirteen years) in California 
during 2010 and 2011.443 Twenty-two percent of students reported 
seeing an advertisement for medical marijuana services at least once 
during a three-month period in 2010.444 The frequency increased to 
thirty percent in 2011.445 Adolescents who saw medical marijuana 
advertising were more likely to either report using marijuana or to say 
they planned to use it in the future.446 The study is significant because 
onset of cannabis use during early adolescence has been correlated with 
neuropsychological performance deficits, poor school performance, and 
concomitant use of illicit drugs.447 RAND recommended regulating 
medical marijuana advertisements in the same fashion as alcohol and 
tobacco products.448 
 
439. Ariz. Revised Statute § 36-2801(3) (West 2010). Debilitation medical 
conditions include: cancer, glaucoma, positive status for human 
immunodeficiency virus, acquired immune deficiency syndrome, hepatitis 
C, amyotrophic lateral sclerosis, Crohn’s disease, and agitation of 
Alzheimer’s disease. 
440. Colo. Code Regs. § 212-2 (2018). 
441. Id. 
442. RAND CORPORATION, https://www.rand.org/about/history.html (last 
visited Oct. 21, 2018). Research and Development (RAND) is a non-
partisan corporation that performs research and provides analysis to 
inform policy decisions. 
443. Elizabeth J. D’Amico et al., Gateway to Curiosity: Medical Marijuana 
Ads and Intention and Use During Middle School, 29 PSYCHOLOGY OF 
ADDICTIVE BEHAVIORS 613, 614 (2015). 
444. Id. at 615. 
445. Id. 
446. Id. 
447. Emily D’Amico, Adolescents Who View Medical Marijuana Advertising 
Are More Likely 
to Use the Drug, RAND CORPORATION (Jul. 6, 2015), https://www.rand.org 
/news/press/2015/07/06.html. 
448. Id. 
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To make cannabis less appealing to youth, California Senator Ben 
Allen introduced Senate Bill 162, which would prohibit marijuana 
dispensaries, producers, and growers from advertising their businesses 
on clothing, hats, or other promotional merchandise.449 The Bill also 
prohibits cannabis advertising within 1,000 feet of a daycare, grade 
school, playground, or youth center.450 The legislation is endorsed by 
the RAND Drug Policy Research Center and supported by the 
American Academy of Pediatrics.451 The Bill has been referred to the 
Committee on Appropriations.452 
A bill to ban billboard advertising for medical marijuana, 
dispensaries, and businesses that promote medical marijuana has been 
introduced in Michigan and approved by the Senate Judiciary 
Committee in late September 2017.453 
Twitter is a social media platform with over 300 million monthly 
users.454 With its short messages and photos, it establishes trends and 
influences the consumption of goods and services.455 Online magazines 
frequently list the most followed and influential cannabis-related 
 
449. Dennis Romero, T-Shirts and Hats Used to Advertise Pot Products Could 
Be Banned, L.A. WEEKLY (June 26, 2017, 6:03 AM), 
https://www.laweekly.com/news/california-law-would-ban-some- 
marijuana-branded-clothing-8361493. 
450. S.B. 162, 2017 Leg. Sess. (Cal. 2017). 
451. California Bill Seeks to Ban Branded Cannabis Merchandise, COLUM. 
NORML (Sept. 3, 2017), http://columbianorml.org/norml-news/ 
california-bill-seeks-to-ban-branded-cannabis-merchandise/; Michael Kim, 
Senate Aims to Protect the Youth of California by Banning the Use of 
Branded Merchandise in Cannabis Advertising, CKB VIENNA (Oct. 10, 
2017), https://www.ckbvienna.com/blog/2017/10/31/senate-aims-to-
protect-the-youth-of-california-by-banning-the-use-of-branded- 
merchandise-in-cannabis-advertising. 
452. S.B. 162, 2017 Gen. Assemb., Reg. Sess. (Cal. 2017). 
453. Senate Panel OKs Jones Bill to Regulate Medical Marijuana Ads, Senator 
Rick Jones (Sept. 27, 2017), 
http://www.senatorrickjones.com/senate-panel-oks-jones-bill-to- regulate-
medical-marijuana-ads/. 
454. Number of Monthly Active Twitter Users Worldwide, STATSIA, 
https://www.statista.com/statistics/282087/number-of- monthly- active-
twitter-users/ (last visited Oct. 4, 2018). 
455. Id. 
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Twitter accounts.456 Weed Tweets, with 1.23 million followers, is 
number one.457 High Times Magazine, with 640,000 followers, is 
considered a major influencer in the marijuana market.458 Follower age 
is not restricted. If the cannabis industry is sending out pro-marijuana 
information on Twitter, the followers are subjected to industry 
marketing regardless of age.459 
Researchers studied the content of tweets and the demographics of 
the followers of @stillblazingtho, a pro-marijuana Twitter handle with 
over one million followers.460 Eighty-two percent of the comments were 
positive about marijuana.461 The majority of followers (seventy-three 
percent) were nineteen-years old or younger.462 Because this age 
category is highly influenced by social media and tends to establish 
patterns of drug use at an early age,463 Twitter has enormous power, 
but no restraints, when it comes to advertising marijuana to youth. 
Some states may be aggressive in limiting youth marketing of 
marijuana while others will be laissez-faire in legislation and 
enforcement. Prudent cannabis growers, manufacturers, and dispensers 
can take steps to ensure that their advertisements and marketing do 
not target youth. 
Historically, tobacco companies were sued for improperly directing 
their marketing and advertising at youth, exposing young people to 
tobacco and tobacco addiction at a young age.464 At present, Juul Labs, 
 
456. Top 10 Twitter Accounts for Cannabis Lovers, ZAMNESIA, 
https://www.zamnesia.com/blog-top-10-twitter-accounts-for-cannabis- 
lovers-n1694 (last edited Apr. 10, 2018); Top 20 Most Influential 
Marijuana Related Twitter Accounts, HOW TO GROW BUD (May 6, 2010), 
http://www.howtogrowbud.com/top-20-most-influential-marijuana-
related-twitter-accounts/; George Gott, Weed Twitter Accounts to 
Follow, POTENT (2016), https://potent.media/weed-twitter-accounts-to-
follow; Jennifer Kregor, Cannabis Industry Social Media Showdown - 
March 2018, BRIGHTFIELD GROUP (Mar. 5, 2018), 
https://www.brightfieldgroup.com/post/cannabis- industry-social-media-
showdown-march-2018. 
457. ZAMNESIA, supra note 456. 
458. Id. 
459. Patricia Cavazos-Rehg et al. Characterizing the Followers and Tweets of 
a Marijuana-Focused Twitter Handle, 16 J. MED. INTERNET RES. e157, 
e157 (2014). 
460. Id. 
461. Id. 
462. Id. 
463. Id. 
464. Laura Bach, Tobacco Company Marketing to Kids, CAMPAIGN FOR 
TOBACCO-FREE KIDS (Apr. 10, 2018), https://www.tobaccofreekids.org/ 
assets/factsheets/0008.pdf. 
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an e-cigarette manufacturer, is in a nationwide class action.465 The 
Plaintiffs allege that Juul marketed its product as safe and targeted 
youth at the outset.466 A plaintiff could raise a similar claim against the 
marijuana industry - a youth marketing claim - if advertisements or 
marketing efforts are directed at youth. 
IX. Conclusion 
The marijuana industry is in its infancy. Most of the industry’s 
energy has been spent on cultivating, manufacturing, and distributing 
a profitable product without attracting too much attention from federal 
prosecutors. Products liability litigation in medical marijuana is just 
starting. It will grow and mature over the next two decades. 
Medical marijuana shares characteristics with alcohol, tobacco, and 
nutritional supplements, but it is most analogous to pharmaceuticals. 
Product liability claims for medical marijuana will most resemble claims 
for pharmaceuticals, except that the Learned Intermediary Doctrine 
will be minimally applicable. Defective design and failure to warn claims 
are the most likely ones to prevail. They will predominantly be 
grounded in negligence and strict liability in tort. 
At present, damages are difficult to assess because adequate 
medical research has not been done. However, it is clear that damages 
will be both short term and long term. In the short term, injuries will 
be related to an acute overdose with claims filed by consumers and 
injured bystanders. The evidence will show that products were 
improperly evaluated or inadequately labeled. Injured patients will 
prove that they were not instructed in the proper use of cannabis or in 
its potential side effects. All participants in the supply chain may be 
held liable for these misadventures. 
Manufacturers and retailers can effectively mitigate liability in two 
ways. First, they can keep current with the latest scientific and medical 
information about cannabis and educate or warn their customers 
accordingly. Second, they can develop and market safer products. These 
include, inter alia, single dose, individually wrapped, edibles sold in 
child resistant packaging with CBD to THC ratios that are 
therapeutically effective and optimally safe. Liability cannot be 
designed or warned away, so insurance will be used to transfer the risk. 
I predict that state governments will act to provide safer products 
and limit marketing to youth while promoting cannabis research. The 
 
465. Deanna Paul, E-Cigarette Maker Juul Targeted Teens with False Claims 
of Safety, Lawsuit Says (July 30, 2018), https://www.washingtonpost 
.com/news/to-your-health/wp/2018/07/30/e-cigarette-maker-juul-
targeted-teens-with-false-claims-of-safety-lawsuitclaims/?noredirect= 
on&utm_term=.50e77f2cdac2. 
466. Pls.’ Compl., Yannuci v. Juul Labs, No. 1:15cv24186 (S.D. Fla Oct. 10, 
2018). 
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DEA will either reschedule cannabis into Schedule II, III, or IV of its 
own accord or will be forced to by Congress. Medical marijuana will 
become accepted by the medical community as further research at home 
and abroad establishes its therapeutic efficacy and the critical nature 
of the endogenous cannabinoid system in the body’s homeostasis. The 
patients, manufacturers, and retailers will greatly benefit from 
regulation that will reduce both injury and liability. 
